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ABSTRACT

Biosynthesis and roles of virulence conferring cell wall associated dimycocerosate esters in Mycobacterium
marinum
by
Poornima Mohandas

Advisor: Dr. Luis E.N. Quadri

Mycobacterial species include a variety of obligate and opportunistic pathogens that
cause several important diseases affecting mankind such as tuberculosis and leprosy. The most
unique feature of these bacteria is their intricate cell wall that poses a permeability barrier to
antibiotics and contributes to their pathogenicity and persistence within the host. The cell wall
hosts several complex lipids such as dimycocerosate esters (DIMs), which are found in many
clinically relevant pathogenic species of mycobacteria. DIMs have been implicated in the
virulence of mycobacteria and play a major role in helping the bacteria evade host immune
responses. It is therefore crucial to define the biosynthesis and role of DIMs in mycobacteria, to
better understand these organisms and identify new drug target candidates. DIMs consist of two
structurally related groups: phthiocerol dimycocerosates (PDIMs) and phenolic glycolipids
(PGLs). PDIMs and PGLs share part of a biosynthetic pathway that consists of two enzyme
families: polyketide synthases (PKSs) and fatty acyl AMP ligases (FAALs).
This dissertation has investigated the roles of PKSs and FAALs during PGL biosynthesis
in the pathogenic nontuberculous mycobacterium; Mycobacterium marinum. More specifically,
it is focused on mutational studies that probed the mechanism by which intermediates
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synthesized by an iterative PKS, Pks15/1 are transferred to a non-iterative PKS, PpsA during
PGL biosynthesis. Our findings specified the role of the loading acyl carrier protein domain of
PpsA, in the capture of intermediates from Pks15/1 during PGL biosynthesis. We also provided
the first evidence supporting a model in which the transfer of intermediates during PGL
biosynthesis is dependent on a novel FAAL enzyme (FadD29) that acts as an intermediary
between Pks15/1 and PpsA, within a nontuberculous mycobacterial species.
This dissertation has also explored the hypothesis that different gene knockouts that
render the same PDIM and/or PGL deficiency phenotypes lead to strains with equivalent
pleiotropic profiles. The availability of six M. marinum mutants, each with a different gene
knockout in the PDIM/PGL biosynthetic pathway, provided an opportunity to probe for the
pleiotropic consequences of gene knockouts leading to PDIMˉ PGLˉ, PDIM+ PGLˉ, or PDIMˉ
PGL+ phenotypes. We evaluated the mutants for changes in cell surface properties, cell envelope
permeability, antimicrobial drug susceptibility, biofilm formation virulence in an amoeba model
system, sliding motility and in vitro growth assays. Our results revealed that the pleiotropic
patterns emerging from the different gene knockouts lead to: altered cell surface properties,
weakened cell envelope permeability barrier, increased antibiotic susceptibility, reduced biofilm
formation and different attenuation levels in an amoeba model. No notable differences were
observed in sliding motility and in vitro growth of the different mutants. Our findings also
advocate that, different enzymes of the pathway whose elimination equally leads to PDIM and
PGL deficiency might not be equivalent drug target candidates.
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CHAPTER 1: INTRODUCTION
“The act of making an addition to the overwhelming literature on acid-fast bacteria
needs an excuse, if not an apology. No other bacterial group has received quite the same
flattering attention or yielded in return so rich a harvest of chemical knowledge; yet no other
group has more stubbornly resisted all efforts to expose the intimate secrets of its metabolism.”
-N.L. Edson (3)
MYCOBACTERIAL SPECIES: CLASSIFICATION AND CHARACTERISTICS
Mycobacteria are a genus of over 150 species in the phylum Actinobacteria (4-6). They
are a group of aerobic, rod shaped bacteria with a high G+C content (50-60%) (6). One of the
most unique features of this group of bacteria is their acid fast cell wall that shares characteristics
with both gram positive and gram negative bacteria. Mycobacteria have been shown by cryoelectron microscopy studies to possess a periplasm similar to gram positive bacteria, along with
an outer membrane composed of unique esoteric lipids as seen in gram negative bacteria, (7,8).
Their habitat includes both terrestrial and aquatic environments in addition to intracellular
environments where they continue to hone their excellent pathogenic skills. Based on their
pathogenic behavior, mycobacteria are most commonly grouped into obligate pathogens,
opportunistic pathogens or non-pathogenic saprophytes (9,10).
Mycobacteria were first identified by Dr. Armauer Hansen in 1873 with the discovery of
Mycobacterium leprae, the causative agent of leprosy (9,11,12). However it was the discovery of
Mycobacterium tuberculosis by Dr. Robert Koch, nine years later that truly kick- started the
study of mycobacteria while simultaneously launching microbiology as a science. By isolating
the bacterium from infected tissue, staining it, culturing it, inoculating it into healthy laboratory
animals, and reproducing the disease, Koch had not only provided strong support for the germ
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theory of disease which was widely contested at the time, he had also indisputably and very
elegantly unveiled the sinister causal agent of mankind’s deadliest disease, known over time as
the white plague, phthisis, consumption or tuberculosis as we call it today (13,14).
TUBERCULOSIS
“If the number of victims is a measure of the significance of a disease, even the most
dreaded infectious diseases such as plague or cholera must rank far behind tuberculosis.”
-Robert Koch (15)
CHARACTERISTICS AND GLOBAL HEALTH PARADIGM
M. tuberculosis is one of the deadliest pathogens known to man. It is the causative agent
of tuberculosis or TB, an air borne disease characterized by the presence of tubercles or
granuloma in the lungs or other tissues in the body (16,17) TB is a major global health problem
and along with HIV has been declared as a leading cause of death from an infectious disease
(18). Approximately one third of the global human population has asymptomatic latent
tuberculosis which comes with the risk of developing into active TB disease that typically
presents itself as a pulmonary or extra pulmonary disseminated disease. The World Health
Organization in 2014 reported that, 9.6 million people around the world were diagnosed with
active TB disease while ~ 1.5 million TB-related deaths were reported worldwide. In the United
States alone a total of 9,421 TB cases were reported at the rate of 2.96 cases per 100,000 persons
in 2014 (18). TB is also a leading killer of HIV-positive individuals, who are 30 times more
susceptible to tuberculosis than individuals who do not harbor HIV. With the advances in the
diagnosis and treatment of TB, it might be encouraging to realize that globally, the mortality rate
of TB has decreased in the last decade, and the incidence of active disease is steadily but slowly
declining by ~1 - 3% per year). However, the burden of disease remains substantial, especially in
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low-income countries an issue compounded by the rise of tuberculosis caused by multi drug
resistant (MDR) and extensively drug (XDR) strains of M. tuberculosis. This is a phenomenon
that is expected to occur considering the fact that M. tuberculosis is a pathogen that has
coevolved with the modern human affecting their morbidity and mortality for at least 20,000
years.
MYCOBACTERIUM TUBERCULOSIS COMPLEX: EVOLUTION AND PHYLOGENY
Tuberculosis is an ancient disease that has been with mankind for thousands of years, and
our relationship with its causative agent, M. tuberculosis has revealed a remarkably parallel
demographic evolution (19,20). The agents of tuberculosis in mammals have been identified as
obligate intracellular pathogens and grouped as the Mycobacterium tuberculosis Complex
(MTBC) in which the predominantly human pathogens include M. tuberculosis, M. africanum,
M. canettii, and members that largely infect animals include M. bovis, M. microti, M. caprae, M.
orygis, and M. pinnipedii. MTBC also encompasses the M. bovis bacillus Calmette - Guérin
(BCG) strains used in the TB vaccine (9,10,19).
M. tuberculosis was originally believed to have evolved from M. bovis, a pathogen of
cattle that spread to humans upon domestication of animals in the neolithic era. (21,22). The
sequencing of the entire M. tuberculosis genome has since exposed evidence suggesting its
evolution approximately 40,000 years ago, from a pool of ancestral tubercle bacilli called M.
prototuberculosis (19,23,24). This ancient precursor strain is believed to have given rise to two
lineages some 20-30,000 years ago; one that exclusively spread among humans and the other that
is thought to have moved through both humans and animals (19). While the whole genome
sequencing of the strains in the MTBC provided valuable insight into the origin of the disease
and its pathogen, it also offers the promise of providing important information that will guide the
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diagnosis, prevention and treatment of the disease especially with the rise in mutations of the
strains that have led to MDR and XDR stains of MTBC (10,20).
TUBERCULOSIS: DIAGNOSIS
The first step in the identification and diagnosis of M. tuberculosis and TB is sputum
smear microscopy where the presence of M. tuberculosis is revealed by the acid fast nature of the
bacillus. This is usually done in combination with chest X-rays and PCR methods to quickly
diagnose active tuberculosis. Tuberculin or the Mantoux test and IFNγ release assays are used to
diagnose latent TB depending on the patient’s immunization status and affordability (17,25).
Detection of the bacilli in the sputum smear requires the presence of a large load of the bacteria
in the sputum (105 CFU/ml) whereas the X-ray and PCR methods are not exactly cheap or
reliable enough to be made available to countries with limited resources. These methods while
being quick do not offer the best diagnosis of TB (10). The true gold standard method for the
identification of the bacilli continues to be culturing of the mycobacteria in a selective media.
This technique is harder to implement and manage because of the slow growth rate of the
bacteria (18-24 hour doubling time) as well as safety requirements surrounding the maintenance
of a biosafety level 3 pathogen (10). Efforts are being made to develop and implement whole
genome sequencing of MTBC isolates from infected candidates to overcome the existing
shortcomings and better aid the diagnosis and treatment of the disease. Nevertheless a 130 year
old sputum smear microscopy test used from the days of Robert Koch continues to be the most
widely used method to detect TB.
TUERCULOSIS: PREVENTION
Vaccines against the disease are extremely limited and have proven to have at best a
variable efficacy against pulmonary TB. The vaccine used against TB is the BCG (bacillus of
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Calmette and Guerin) vaccine named after Albert Calmette and Camille Guérin who derived the
attenuated strain by serially passaging M. bovis which caused the disease in various animal
models. It was first used as a vaccine for prevention of TB in 1921 and continues to be the single
most effective vaccine against TB albeit with variable efficacies (26,27). Studies have shown
that the BCG vaccine is 80% effective against the disseminated forms of TB such as miliary TB
and meningitis in children but offering little to no protection in adults (26).
TUBERCULOSIS: TREATMENT
Tackling M. tuberculosis seemed like an impossible task because of its complex lipid rich
cell wall which fortified the bacterium against most of the antibiotics of the 19th century such as
penicillin and sulfonamides. The treatment options for eradicating tuberculosis were welcomed
with great expectation in the early part of the 20th century with the discovery of an
aminoglycoside, streptomycin by Albert Schatz and Selman Waksman in 1943 (27-29). However
it was observed that M. tuberculosis quickly developed resistance to streptomycin which
necessitated the administration of a cocktail of antibiotics which was strengthened by the
discovery of isoniazid a drug that blocks the biosynthesis of mycolic acid, a key component of
the mycobacterial cell wall and rifamycin, a lipophilic drug that blocks bacterial RNA synthesis
(27,29-31). The current treatment recommendation for active tuberculosis by the WHO warrants
a long and complicated regimen that lasts a minimum of six months and includes a cocktail of at
least four first line drugs – isoniazid, rifampin, pyrazinamide, and ethambutol (18,29). This
treatment plan is expensive and difficult to track leading to the emergence of MDR and XDR
strains of M. tuberculosis that has confounded the scientific community and contributed to the
tragedy of tuberculosis. MDR-TB occurs as a result of in vitro resistance to the two first-line
drugs, isoniazid and rifampin while XDR-TB is resistant not only to isoniazid and rifampin, but
also to other antibiotics like kanamycin, amikacin, or capreomycin, that are used in drug resistant
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TB therapy (32) The emergence of these strains emphasizes the urgency to investigate the ins
and outs of mycobacterial pathogenesis in order to curb the alarming rise of the TB epidemic and
death in millions of humans every year.
NONTUBERCULOUS MYCOBACTERIA
All mycobacteria that are indigenous to various environmental niches and are not obligate
pathogens like their counterparts in the MTBC and M. leprae, are classified as nontuberculous
mycobacteria or NTMs (33-35). These mycobacteria are referred to by different names anonymous or atypical mycobacteria, mycobacteria other than tuberculosis (MOTT) and
nontuberculous mycobacteria (NTM) (36). NTMs include opportunistic mycobacterial pathogens
like Mycobacterium avium, Mycobacterium kansasii which cause tuberculosis like infections in
patients with immune or respiratory defects (33,37) as well as nonpathogenic saprophytes such
as Mycobacterium smegmatis and Mycobacterium phlei (38). They were classified into four
groups by Dr. Ernest Runyon based on their growth properties (slow or rapid) and their ability to
produce pigment (photochromogens: pigmented in the presence of light; scotochromogen:
pigmented in the presence or absence of light; non- chromogens: non-pigmented) (9,34,39).
While the clinical relevance of NTMs is indisputable, their phylogenetic closeness to the MTBC
adds to their applicability in the context of serving as model systems to understand the evolution
and pathogenicity of M. tuberculosis (21,23,40-42).
MYCBACTERIUM MARINUM
M. marinum is an environmental mycobacteria with a wide range of host preferences. It is
typically found in aquatic environments where it is able to survive as a pathogen of
poikilotherms such as frogs and fish (40,43,44). The bacterium was first isolated by Joseph D.
Aronson in 1926 from the tubercle lesions of diseased fish. It was later isolated from swimming
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pool associated human granulomatous skin lesions called fish tank or aquarium tank granuloma
in the 1950s which established M. marinum as a relevant human pathogen albeit
opportunistic(40,44). The disease is typically limited to the skin and soft tissues extremities and
is pathologically indistinguishable from dermal infections caused by M. tuberculosis. This M.
marinum disease necessitates treatment with anti-tuberculosis drugs such as rifampin,
ethambutol, and quinolones, as well as other agents such as doxycycline and clarithromycin and
like tuberculosis long-term antibiotic treatment is required due to the development of antibiotic
resistance in the infecting bacteria (35,40).
M. marinum shares most of its growth and physiological properties with M. tuberculosis.
However, compared to the ~ 20 hour generation time of M. tuberculosis, M. marinum is a
relatively rapid growing NTM with a division time of 6-8 hours during log phase. It is a
photochromogen that produces bright yellow pigment when exposed to light (43)and grows at an
optimum temperature of 25°C - 35°C unlike M. tuberculosis which grows optimally at 37°C
(45). M. marinum has a large genome of ~6.6 MB, about 50% more than the size of the genome
of M. tuberculosis which is ~ 4.4 MB and smaller due to its exclusive host niche preferences
(40). The M. marinum genome shares 3000 orthologous genes with M. tuberculosis with amino
acid identity averages of ~85% between the orthologs (40,46). Phylogenetic studies have shown
that M. marinum is most closely related to Mycobacterium ulcerans with a >97% nucleotide
identity and then to M. tuberculosis with a >85% nucleotide identity (38,40,47). Genome
comparison data have indicated that M. marinum and M. tuberculosis deviated from a common
environmental mycobacterium with M. marinum retaining genes required for its dual lifestyle
and M. tuberculosis undergoing reductive evolution compatible with its intracellular, parasitic
lifestyle(40). These studies also advocate a common prototype for both their pathogenesis
approaches. Due to its phylogenetic similarity to M. tuberculosis and its ease of use as a
7

biologically safer and faster growing organism, M. marinum has consequently emerged as a
model for M. tuberculosis pathogenesis (40,46,48).
CELL ENVELOPE OF MYCOBACTERIA
Mycobacteria are surrounded by a very complex and unique cell envelope layer. Its
uniqueness stems from its unusually esoteric and high lipid composition which constitutes about
40% of the dry weight of the cell (49,50). The cell envelope not only contributes to the rigidity
and shape of the bacterium but also plays an active role in its interaction with the host during
infection. It has long been thought of as the permeability barrier conferring intracellular
resilience to the bacterium. It is also responsible for the resistance of the bacterium towards
many antibiotics while simultaneously being the target of the antibiotics that are effective in the
treatment of mycobacterial infections (5).
Several models have been proposed to describe the organization and architecture of the
mycobacterial cell envelope. The model proposed by Minnikin in 1982 which was later
supported with cryo-electron microscopy studies are in consensus that the cell envelope includes
the plasma membrane, the cell wall and an additional electron transparent capsule layer
(8,49,51). These studies also revealed a periplasm layer separating the plasma membrane from
the outer membrane, a conformation similar to that observed in gram negative bacteria (7,8,50)
(Figure 1).
PLASMA MEMBRANE
Mycobacteria have a typical plasma membrane which is a bilayer composed of polar
lipids such as phosphatidylinositol, phosphatidylethanolamine and diphosphatidylglycerol. In
addition to the conventional lipids, the mycobacterial plasma membrane also supports various
glycosyl phosphopolyprenols and phosphotidylinositol mannosides (PIMs) and its variants which
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are extractable phospholipids unevenly distributed throughout the membrane. PIMs extend into
the outer layers of the mycobacterial cell envelope, reinforcing its selective permeability (5,41).
PIMs are involved in anchoring polysaccharides like lipoarabinomannan (LAM) and lipomannan
(LM) in the cell wall (43,52-54). The plasma membrane also hosts carotenoids, compounds
known to contribute towards the photochromogenic properties of some mycobacteria and
menaquinones which are compounds thought to be active in electron transport (51).
CELL WALL
Mycobacteria along with Corynebacteria and Nocardia produce a unique a chemotype IV
cell wall that is essential for their viability (5,31,55). The cell wall of mycobacteria is an
asymmetric lipid bilayer composed of an inner leaflet containing mycolic acids and an outer
leaflet composed of extractable lipids (49,56) (Figure 1).
INNER LEAFLET
The inner leaflet also known as the cell wall core is responsible for the basic structural
integrity of mycobacteria and their resilience towards antibiotics due to extremely low
permeability (5,49,57). It is composed of three covalently linked molecules; peptidoglycan,
arabinogalactan and mycolic acid (Figure 1). The peptidoglycan layer surrounds the plasma
membrane and lays the foundation and framework of the cell wall core. Unlike the peptidoglycan
layer in most eubacteria which is composed of N-acetyl-glucosamine (NAG) and N-acetylmuramic acid (NAM), mycobacteria possess a distinct layer in which the muramic acid is Nglycosylated which confers resistance to typical antibacterial agents like lysozyme that target the
peptidoglycan (5,58). Mycobacterial peptidoglycan is covalently linked via a phosphodiester
linkage to the arabinogalactan layer. Arabinogalactan is a complex polysaccharide composed of
arabinan and galactan units in the furanose form that is unique to mycobacteria. One end of the
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arabinogalactan layer is covalently linked to the peptidoglycan layer while the other end is
intermingled with mycolic acid residues (5,31).
Mycolic acids are the most exceptional lipid of the cell wall core of all mycobacteria.
They are α- branched β-hydroxy acids composed of up to 90 carbon atoms. They are made up of
a long branch known as the meromycolate that is more versatile and a shorter branch known as
the alpha-branch which is conserved among the family of mycobacteria (5,57,59). There are
three classes of mycolic acids; the α-mycolate, methoxymycolate and the ketomycolate. Each
mycobacterial species has a distinct ratio of these classes of mycolic acids which contributes to
the differences in hydrophobicity of their cell wall (41). The mycolic acids are proposed to be
packed side by side, perpendicular to the plane of the cell surface (50,54) They exist in the cell
wall in two basic forms: covalently bound to arabinogalactan in the cell wall core, and as
loosely-associated entities that are esterified to a variety of carbohydrate-containing molecules
and distributed throughout the cell wall (59,60).
OUTER LEAFLET
The outer leaflet of the mycobacterial cell wall is composed of extractable lipids that
contribute to the asymmetry of the lipid bilayer. This layer is highly fluid/permeable in contrast
to the inner leaflet. While the outer leaflet hosts most of the extractable lipids, these extractable
lipids are also distributed throughout the cell envelope. Triacylglycerols (TAGs) and the mycolic
acid derived lipids such as trehalose dimycolates (TDM) are some of these extractable lipids that
are ubiquitous to all mycobacteria. Lipooligosaccharides (LOS), phenolic glycolipids (PGLs),
phthiocerol dimycocerosates (PDIMs), Diacyl trehalose (DATs), Pentaacyl trehalose (PATs),
Sulfoglycolipids (SGLs) and glycopeptidolipids (GPLs) are extractable lipids that are found in
the outer leaflet of the mycobacterial cell wall in a species specific manner (5,61) (Figure 1).
These lipids also range in polarity from the hydrophilic LOSs, through PGLs, DATs, SGLs and
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PATs, to the highly apolar hydrophobic PDIMs (54). This spectrum in the polarity and the
species specific diversity of the outer membrane lipids adds to the fascinating complexity of the
mycobacterial cell envelope.
CAPSULE
The outermost compartment of the mycobacterial cell envelope consists of an electron
transparent layer called the capsule (Figure 1). The capsule hosts a wide variety of a readily
soluble mixture of polysaccharides, proteins and lipids. The major capsular polysaccharides are
glucan, arabinomannan and mannan. Glucan is the most abundant polysaccharide in the M.
tuberculosis capsule (62). The components of the capsule are believed to act as effector/signaling
molecules actively involved in the pathogenic behavior of the bacterium and play a crucial role
in host pathogen interactions (49,56).
BIOSYNTHESIS OF CELL WALL LIPIDS
Due to its known impact on the resilience and pathogenesis of mycobacteria, biosynthesis
of cell wall associated mycobacterial lipids has been extensively investigated over time. Apart
from fatty acid synthases (FASs), the most significant group of enzymes associated with the
biosynthesis of mycobacterial lipids are polyketide synthases (PKSs). Other pathway associated
enzymes such as fatty acyl AMP ligases are also critical to the biosynthesis of cell wall lipids.
POLYKETIDE SYNTHASES
Most of the unique lipids and glycolipids of the mycobacterial cell envelope are
synthesized by enzyme systems called polyketide synthases or PKSs. PKSs are large multi
modular enzymes similar to fatty acid synthases (FASs) that are responsible for the synthesis of
secondary metabolites or polyketides. In a process reminiscent of fatty acid biosynthesis, PKSs
implement a succession of decarboxylative claisen-like condensations of activated two-carbon
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starter units of acetyl CoA or malonyl CoA. PKS elongates the polyketide chain either by
repetitively using a single active site to perform multiple condensation reactions or by using a
modular assembly line mechanism (63,64). Based on their biosynthetic strategies, PKSs are
classified into three types i.e., type I, type II, or type III Type I PKSs are further categorized as
modular and iterative. A typical modular type I PKS has distinct functional domains or catalytic
units on a single protein that is organized in a module, and each domain in a module is utilized
only once during polyketide product formation. In contrast, in a typical iterative type I PKS, each
functional domain of those clustered on a single protein is used repeatedly during the assembly
of the polyketide product. Type II PKSs are multienzyme complexes that catalyze a single set of
iteratively acting reactions during formation of the polyketide product. Type III PKSs, also
known as chalcone synthases has been recently discovered in bacteria and belongs to the plant
chalcone synthases superfamily of condensing enzymes. They are homodimeric enzymes that are
structurally and mechanistically distinct from type I and type II PKSs (65-67).
The catalytic domains incorporated within PKSs are covalently linked in very long
polypeptides and typically include a β-ketosynthase (KS), acyl transferase (AT), dehydratase
(DH), enoylreductase (ER), β-ketoreductase (KR), acyl carrier protein (ACP) and thioesterase
(TE) (68). The AT domains are responsible for maintaining the substrate selectivity and
specificity while the KS domain carries out the key claisen condensation reaction. The AT, KS
and ACP are the essential domains present in all PKS modules. Additional domains like the ER,
KR and DH domains all carry out various specific reductive processing leading to the complex
structure of the resulting polyketide. The discretionary TE domain which is present at the end of
the assembly line, is responsible for chain termination and release of the final polyketide (68-70).
All through the synthesis process, the incomplete polyketide chains are tethered to the ACP
domain through long ‘swinging arms’ or the phosphopantetheinyl group, which ensures that the
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polyketide intermediate is correctly steered to the various domains within a given PKS. The
product synthesized by a PKS is very often only an intermediate on the way to becoming a
bioactive compound. Once it is released from the PKS, it is processed by a host of other ‘postPKS’ enzymes which add functional groups (methyls, hydroxyls and carbonyls, among others) or
which decorate the polyketide base structure with sugars as seen in the case of some
mycobacterial lipids (70).
Until recently PKSs were assumed to be mostly limited to the biosynthesis of secondary
metabolites; however PKSs identified in mycobacteria have provided a new dimension to their
functional versatility (66). Ahead of the genome sequence revelation, Kolattukudy and
colleagues were the first to report the occurrence of PKSs in mycobacteria. They suggested that
the biosynthesis of mycocerosic acids a key structural component of PDIMs and PGLs, required
the catalytic activity of a modular PKS similar to that seen in erythromycin biosynthesis (71,72).
Since then a number of PKSs have been implicated in the biosynthesis of various mycobacterial
cell wall lipids. The genome sequence of M. tuberculosis exposed the presence of a large number
of PKS-like genes explaining in part the presence of a number of lipid metabolites unique to M.
tuberculosis (73). Data from various genome projects indicate that several gene clusters
homologous to all three PKS systems are present in the mycobacterial genome and their
differential distribution across species can be correlated with type specific variations in their
lipid profile. There are 24 genes encoding PKS homologs in the genome of M. tuberculosis strain
H37Rv (65,73). These PKS-encoding genes total about 103,644 bp, which is 2.6% of the total
protein coding bases (4,027,296 bp) of the M. tuberculosis chromosome (65,73).
PKSs in M. tuberculosis work in conjunction with FASs to produce complex lipids such
as mycolic acids, PGLs, PDIMs, sulfolipids and mannosyl-β-1-phosphomycoketides (MPMs)
many of which are essential for its survival. This association between FASs and PKSs in
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mycobacteria is made possible by a family of enzymes called fatty acyl-AMP ligases (FAALs),
which activate fatty acids as acyl-adenylates. The mycobacterial PKSs then use various
biochemical mechanisms to extend these fatty acyl precursors to produce novel lipid compounds
that decorate the cell wall.
FATTY ACYL AMP LIGASES
Quite a few non-PKS genes have also been implicated in the biosynthesis of the
mycobacterial cell wall lipids. Among them the fadD genes deserve special mention since they
encode important acyl activating adenylating enzymes that are essential for lipid metabolism
(73). They encode two specific groups of enzymes called fatty acyl-AMP ligases (FAALs) and
fatty acyl-coA ligases (FACLs) based on their ability to convert fatty acids into fatty acyladenylates or fatty acyl CoA intermediates respectively. This mode of activation is analogous to
the adenylation domains of nonribosomal peptide synthetases (NRPSs), which along with FAAL
and FACL proteins constitute a large superfamily of acyl-activating enzymes (AAEs) (74).
Within the context of lipid metabolism, the FAALs are involved in lipid biosynthesis, while the
FACLs play a predominant role in the breakdown of lipids. Therefore, the metabolic fate of the
activated fatty acid is dictated by whether it is activated as an acyl-CoA thioester, for energy
generation, phospholipid biosynthesis etc., or as an acyl-AMP, for complex lipid synthesis (7476). The M. tuberculosis genome has sequences encoding 12 FAALs and 22 FACLs (77). M.
marinum being an environmental mycobacteria that is equipped to persist intracellularly, has a
larger genome that encodes for 32 FACLs and 14 FAALs, six of which are shared with M.
tuberculosis (FadD25, FadD26, FadD28, FadD29, FadD30, FadD32), that were predicted by
sequence analysis (40). Interestingly several FAAL members are located next to PKS and NRPS
gene clusters in the M. tuberculosis genome. To establish a functional crosstalk with PKS
enzymes in generating complex cell wall associated lipids, it has been shown that the FAAL
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proteins transfer activated fatty acids to the neighboring PKSs for further chain extension. The
discovery of FAALs in mycobacteria has provided a novel take on fatty acid activation. By
activating fatty acids as acyl adenylates, these proteins redirect the metabolic flux toward
biosynthesis of complex lipid metabolites and are therefore crucial nodes in the biosynthetic
network of virulent lipids (75.).
DIMYCOCEROSATE ESTERS (DIMs)
Dimycocerosate esters (DIMs) consist of an entire family of methyl branched lipids that
are among the most studied cell wall associated lipids of mycobacteria. They are non-covalently
bound within the outer leaflet of the mycobacterial cell wall and occur only in pathogenic
mycobacteria like M. tuberculosis, M. marinum, M. ulcerans, M. kansasii, M. bovis, M. leprae,
M. africanum, M. microti, M. haemophilium (78). They consist of two structurally-related groups
of lipid diesters of long-chain multi methyl-branched fatty acids (mycocerosic acids), called
PDIMs and PGLs. PDIMs or phthiocerol dimycocerosates are the aliphatic non glycosylated
derivatives of β-diols called phthiocerols whereas PGLs or phenolic glycolipids are glycosylated
lipids that share the same conserved β-diol core as PDIMs with a variable carbohydrate moiety
(79) (Figure 3). Within various strains of M. tuberculosis, PDIMs are thought to be produced by
all strains of M. tuberculosis, except those that have lost its production capacity due to
spontaneous mutations from in vitro culturing (65). Unlike PDIMs, PGLs are produced only by a
subset of M. tuberculosis strains (e.g., strains of the W-Beijing family). This trait is speculated to
contribute to the characteristic epidemic spread of M. tuberculosis and its increased likelihood of
developing drug resistance (65,78).
DIMs were identified from the lipid extracts of mycobacteria in the early part of the 20th
century (78) and were believed to play a predominant role in the “public relations” of
mycobacteria due to their peripheral location on the cell wall (80). The role of DIMs as
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significant cell wall associated virulence factors was established when two different groups
simultaneously applied the signature-tagged mutagenesis system to select for mutants unable to
grow in a high-dose intravenous challenge mouse model of tuberculosis (81,82). These studies
conclusively demonstrated DIMs as one of the key players in the interaction of M. tuberculosis
with its host, providing the much needed impetus to better understand the virulence strategies of
this exceptional pathogen. Since then a combination of both genetic and biochemical studies
have contributed to the assembly of a comprehensive portrait of DIM biosynthesis thus
cementing its distinctive relevance in the biology of M. tuberculosis.
DIM BIOSYNTHESIS: OVERVIEW
The biosynthesis of DIMs is a complex process that requires the coordinated activity of
several PKSs and associated enzymes like FAALs (Figure 2). The DIM locus in M. tuberculosis
contains seven different type I PKSs; PpsA, PpsB, PpsC, PpsD, PpsE, Pks15/1and Mas (52,65).
PpsA-E are modular type I PKSs that add the precursors in a sequential assembly line-like
manner, while Mas is a type I PKS that uses an iterative mechanism where the same active sites
are used repetitively to produce the final product (52,72,75). PpsA-E and Mas are shared by both
PDIMs and PGLs during biosynthesis. Pks15/1 on the other hand is also a type I iterative PKS
similar to Mas, but it is implicated specifically in PGL biosynthesis (83). These PKSs act in
conjunction with FAALs whose genes are located nearby within the DIM locus. The DIM locus
hosts four ORFs that encode FAALs, more commonly known as FadD proteins, which activate
and transfer biosynthetic intermediates onto the various PKSs. Among the FAALs involved in
DIM biosynthesis FadD28 has been implicated in the biosynthesis of the mycocerosic acid group
shared by both PDIMs and PGLs, while FadD26 has been implicated specifically in the
biosynthesis of PDIMs (81,84-86). The FadD22 and FadD29 on the other hand are nonredundant
enzymes that are specifically relevant in PGL biosynthesis (87,88). The available data on the
16

biosynthesis of DIMs have led to the proposal of a model that can be summarized in the
following steps (Figure 2):
1. Priming of PpsA with appropriate PGL or PDIM-specific fatty acyl starter unit.
2. Extension of the primer unit by the PKS, PpsABCDE, leading to the generation of the
phthiocerol/phenolphthiocerol entity.
3. A thioesterase (TesA)-dependent release of the polyketide products thioesterified to PpsE
(89-91)
4. Priming of Mas with acyl adenylates of long chain fatty acids by FadD28.
5. Extension of the fatty acyl adenylate and subsequent biosynthesis of mycocerosic acids
by Mas.
6. Trans-esterification

of

mycocerosic

acids

with

the

diol

component

of

phthiocerol/phenolphthiocerol by the polyketide-associated protein A5 (PapA5) and final
assembly (92,93).
The priming of PpsA during phenolphthiocerol synthesis is preceded by reactions that
emphasize the significance of the Pks15/1 enzyme as well as the FadD22 and FadD29 that are
exclusively utilized during PGL biosynthesis. PGL biosynthesis is initiated by the metabolic
intermediate called chorismate, which is converted to p-hydroxybenzoic acid (p-HBA) by a
chorismate pyruvate-lyase, Rv2949c (52,78,94). p-HBA is then activated by FadD22 and
transferred to the Pks15/1 enzyme which extends p-HBA to form the p-hydroxyphenylalkanoate
(PHPA) intermediate (95). The PHPA chain is then transferred to PpsA for PGL biosynthesis
(88). During PDIM biosynthesis, FadD26 utilizes a novel acyl adenylation activation mechanism
to prime PpsA (86). Subsequent to the priming of PpsA, the biosynthesis of PGLs and PDIMs
follow the same biosynthetic route. In addition to the enzymes mentioned above, DIM
biosynthesis also necessitates the involvement of accessory enzymes that further decorate the
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DIM structure, creating an intricately designed pathway that is responsible for the production of
a whole array of the DIM family of lipids.
POLYKETIDE SYNTHASES IN DIM BIOSYNTHESIS
PpsABCDE
The PKSs PpsA-E are implicated in the production of phthiocerol and phenolphthiocerol
components of PDIMs and PGLs respectively (65,96). The pioneering studies of Kolattukudy
and colleagues established the first genetic evidence for the association of ppsABCDE gene
cluster with the production of DIMs (97). They demonstrated in M. bovis Bacille-CalmetteGuerin (BCG), a PDIM- and PGL-producing species, that replacement of the ppsB-ppsC
segment from the ppsABCDE cluster, with a hygromycin-resistance gene cassette renders a
mutant incapable of producing both PDIMs and PGLs (97). In vitro enzymology studies probing
the function of M. tuberculosis PpsA, PpsB and PpsE by Trivedi and coworkers concluded that,
a) PpsA is necessary for the initiation of (phenol) phthiocerols synthesis through the extension of
long-chain fatty acids, b) PpsA and PpsB are necessary for the biosynthesis of the β-diol
functionality of (phenol) phthiocerols, and c) PpsE is required in the final acyl chain extension
step of (phenol) phthiocerol biosynthesis (96). Since then the domain arrangement and function
of each protein in the PpsABCDE system, has been predicted and progressively refined to the
present-day model (65).
Mas
The PKS Mas synthesizes mycocerosic acid which is esterified onto the phthiocerol and
phenolphthiocerol units to generate PDIMs and PGLs respectively. Kolattukudy and colleagues
in their series of iconic papers uncovering DIM biosynthesis, also established mas as the
mycocerosic synthase encoding gene (71,98). They showed that in M. bovis BCG, replacement
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of the mas gene with a hygromycin resistance marker produces a mutant lacking mycocerosic
acids as well as PDIMs and PGLs. The group also delineated the enzymatic role of Mas, in the
biosynthesis of mycocerosic acids (99). They showed that Mas can extend n-fatty acyl primers to
produce mycocerosic acids. This study was corroborated more recently by Trivedi et al who
characterized the mycocerosic acid synthase activity of Mas from M. tuberculosis H37Rv
generated recombinantly in E. coli (96). Overall, these studies have effectively validated Mas as
an iterative type I PKS involved in DIM biosynthesis, a finding consistent with the domain
organization predicted for the protein.
Pks15-1
The initial link between the pks15/1 gene locus and production of PGLs was established
by Constant and colleagues in M. bovis (83). However due to a frameshift mutation in this gene,
the H37Rv type strain of M. tuberculosis is devoid of PGLs. Constant et al demonstrated that this
PGL-deficiency arises from natural sequence polymorphisms that split the parental pks15/1 gene,
found in the PGL-producing mycobacterium species like M. bovis strain BCG, into the
individual genes pks1 and pks15 found in certain PGL-deficient M. tuberculosis strains. Quadri
and colleagues established that, Pks15/1 is a 6-domain reducing iterative type I PKS. It uses
malonyl-CoA as donor to extend a p-HBA starter unit to produce long-chain PHPA biosynthetic
intermediates required for the biosynthesis of the phenolphthiocerol component of PGLs (95).
FATTY ACYL AMP LIGASES IN DIM BIOSYNTHESIS
FadD26, FadD28, and FadD29
The fadD genes with the mycobacterial DIM locus have been proposed to encode FAALs
based on genetic and biochemical studies. Overall, these studies indicated that insertions in
fadD26, fadD28 abrogate PDIM production (81,85,100), and that FadD29 is required for
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biosynthesis of PGLs, yet dispensable for PDIM production (88). Kolattukudy and colleagues
initiated the enzymology studies on FAALs and their role in DIM biosynthesis (84). They
reported the homology of the FadD28 ortholog in M. bovis BCG to acyl adenylate-forming
enzymes and concluded that the enzyme was an acyl-CoA synthase-like protein that catalyzes
formation of CoA thioesters of fatty acids. Subsequently Gokhale and colleagues systematically
delineated the biochemical function of FadD26, FadD28 and FadD29 proteins from M.
tuberculosis H37Rv (86). The proteins were identified as acyl adenylate-forming enzymes and
not acyl-CoA synthetases, as suggested in the previous studies. They also reported the inhibition
of FadD28 by acylsulfamoyl (acyl-AMS) analogs and demonstrated that FadD26 specifically
transfers the activated fatty acid to the PpsA for further carbon chain extension during PDIM
synthesis (74). Overall, FadD26, FadD28, and FadD29 are proposed to belong to a new class of
adenylation enzymes (FAALs) that activate long-chain fatty acids and transfer them to their
cognate PKS partners for chain extension.
FadD22
FadD22 unlike the other FadD enzymes in the DIM biosynthesis pathway, is an unusual
stand alone, didomain initiation module that loads a p-HBA intermediates instead of fatty acid
units. It is comprised of a p-HBA adenylation domain and an aroyl carrier protein domain
(ArCP) that loads the p-HBA intermediate to the iterative type I PKS Pks15/1 for the formation
of long-chain PHPA products as noted above(87). Mutational analysis of the fadD22 gene in M.
bovis implicated the exclusive role of the gene in PGL production (87). Quadri and colleagues
developed the first specific small-molecule inhibitor of PGL biosynthesis, a p-hydroxybenzoyl
AMP analog called 5′-O-[N-(4-hydroxybenzoyl) sulfamoyl]-adenosine (PHB-AMS) that has
potent and specific activity in PGL producing mycobacterial pathogens. As expected, it does not
inhibit PDIM biosynthesis (for which FadD22 is not required) or mycobacterial growth in vitro.
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The inhibitor work from Quadri and colleagues established the possibility of selectively targeting
DIM biosynthesis and probing the biological relevance of PGLs in mycobacterial biology.
ROLE OF DIMYCOCEROSATE ESTERS IN MYCOBACTERIAL
PATHOPHYSIOLOGY
DIMs play an important role in the virulence of mycobacteria. Their production is
modulated throughout the infection process. Numerous often varied conditions affect DIM
production in mycobacteria, including availability of carbon source, phosphorylation by
serine/threonine kinases, reductive stress and transcriptional regulation upon infection of
macrophages (101,102). Analysis of the global lipid profile of M. tuberculosis shows that the
size and abundance of PDIMs are controlled by the availability of their precursor methyl malonyl
CoA and that this regulation occurs during infection (103,104). During infection, DIMs are
thought to moderate the host innate immune response by modifying the biophysical properties of
the mycobacterial cell wall. They subsequently act as direct effectors of pathogenesis by
mediating cross talk between the infecting mycobacteria and the host immune cells like
macrophages and dendritic cells. They may physically interfere with host membranes in order to
impair immune response-related signaling pathways. It is therefore important to consider the
specific structural features of these lipids like the hydrophobic nature of PDIMs and the
glycosylated groups of PGL in exploring their functional role (105). As a result mutant strains
with deletion of the genes involved in PDIM/PGL biosynthesis have a reduced capacity to infect
human macrophages (105-109).
Cambier et al. investigated the role of PDIMs and PGLs in a M. marinum-infected
zebrafish larvae model system. They proposed that PDIMs physically mask mycobacterial
pathogen associated molecular patterns (PAMPs) thereby preventing their recognition by toll like
receptors. This subsequently led to their evasion of inducible nitric oxide synthase (iNOS) 21

expressing macrophages, which were effective in killing the PDIM mutant through production of
reactive nitrogen species. Cambier et al. proposed that pathogenic mycobacteria, in a strain
specific manner, recruit PDIMs for averting macrophages from their natural function and
establishing infection. In addition to the masking effect of PDIMs, they also reported that, PGLs
are involved in selectively recruiting pathogen permissive macrophages to increase the fitness of
the pathogenic M. marinum within the host (105,110).
PDIM deficient mutants have also been shown to be sensitive to reactive nitrogen
species generated in murine macrophages pre-treated with interferon-gamma and tumor necrosis
factor-alpha (111). Whereas loss of PGLs produced by the M. tuberculosis W-Beijing isolate was
found to correlate with an increase in the release of the pro-inflammatory cytokines; tumor
necrosis factor and interleukins 6 and 12 in vitro causing a ‘hyperlethality’ profile of the
mycobacterium in murine disease models (109). Uncovering the means by which WT M.
tuberculosis avoids killing after infection will lead to a better understanding of its mechanisms of
persistence and may lead to the identification of possible targets for novel therapeutics. It also
remains to be determined how these lipids have an impact throughout the disease as a
consequence of their pleiotropic effects.
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RESEARCH OBJECTIVES
Despite knowing a great deal about the contributions of the cell wall associated DIMs to the
pathophysiology of mycobacteria, there are a lot of gaps that preclude a thorough understanding
of their biosynthesis and role in mycobacteria. This dissertation seeks to unravel some of the
intricacies surrounding DIMs in M. marinum, a nontuberculous mycobacterial pathogen that is a
close genetic relative of the M. tuberculosis complex. The research reported in this dissertation
investigates:

I. The mechanism by which p-hydroxyphenylalkanoate (PHPA) intermediates synthesized by
the iterative FadD22-Pks15/1 system are transferred to the non-iterative PpsABCDE system
for elongation of the phenol phthiocerol moiety during PGL synthesis.
II. The various pleiotropic consequences resulting from the loss of PDIMs and/or PGLs to
further elucidate their relevance in the biology of mycobacteria.
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CHAPTER 2: BIOSYNTHESIS OF MYCOBACTERIAL CELL-ENVELOPEASSOCIATED PHENOLIC GLYCOLIPIDS IN MYCOBACTERIUM MARINUM
INTRODUCTION
Multiple lines of investigation have provided considerable support for the idea that PGLs
and PDIMs are implicated in virulence via complex mechanisms of action that are not fully
elucidated (81,85,100,107-122). These (glyco)lipids are also believed to strengthen the cell
envelope permeability barrier (82,100) and to increase the bacterium’s intrinsic resistance to
antimicrobial drugs (82,89,100,115). The relevance of PGLs in mycobacterial biology
underscores the importance of developing a comprehensive knowledge of its biosynthetic
pathway, which remains incompletely understood.
Previous studies of the PGL biosynthetic pathway have revealed a functional cooperation
between the M. marinum proteins FadD22 (p-HBA ligase/initiation module) and Pks15/1
(iterative type I PKS) for production of PHPA intermediates required for PGL biosynthesis
(87,95). The PHPA intermediates synthesized by the M. marinum FadD22-Pks15/1 iterative
system, which is conserved in PGL producers, are thought to be further extended to form the
phenolphthiocerol moiety of PGLs (Figure 3). The extension of the PHPA intermediates has
been proposed to be carried out by PpsABCDE, a conserved, modular, non-iterative type I PKS
that is known to extend fatty acids to form the phthiocerol moiety of PDIMs in M. tuberculosis
(78,81,85,96,97) (Figure 3). During PDIM biosynthesis, the fatty acids are activated and loaded
by the conserved fatty acyl-AMP ligase FadD26 (Figure 4) onto the loading acyl carrier protein
(ACPL) domain of PpsA, the first acting enzyme of the PpsABCDE system (86,96). However,
the mechanism by which the PHPA intermediates assembled by the FadD22-Pks15/1 system
would be transferred to the PpsABCDE system for acyl chain extension during PGL biosynthesis
remains to be experimentally interrogated.
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Herein, we report a mutational study that interrogates the mechanism by which the
PHPA intermediates are transferred to PpsA, the first acting enzyme of the PpsABCDE system.
The findings of this study support a mechanistic model in which the PHPA intermediates are
activated and loaded onto the loading acyl carrier protein (ACPL) domain of M. marinum PpsA
by a dedicated PHPA-AMP ligase. The conservation of the PGL biosynthetic genes across
species (65,78) (Figure 4) and studies in the M. tuberculosis complex (88) strongly suggests that
the mechanistic insights into PGL biosynthesis gained herein are applicable to other PGL
producers. Overall, these studies advance our understanding of the biosynthesis of an important
group of mycobacterial cell envelope-associated glycolipids.
MATERIALS AND METHODS
Culturing conditions, recombinant DNA manipulations, and reagents. M. marinum
strain M (ATCC BAA-535) and its derivatives were cultured under standard conditions in
Middlebrook 7H9 (Difco) supplemented with 10% ADN (5% BSA, 2% dextrose, 0.85% NaCl)
and 0.05% Tween-80 (supplemented 7H9) or on Middlebrook 7H11 agar (Difco) with ADN
(supplemented 7H11) (123). The strains used in this study are listed in (Table 1). Escherichia
coli strains were cultured under standard conditions in Luria-Bertani (LB) media (124). When
required, kanamycin (30 μg ml-1), hygromycin (50 μg ml-1), sucrose (2%) and/or 5-bromo-4chloro-3-indolyl-β-D-galactopyranosid (X-gal, 70 μg ml-1) were added to the growth media.
DNA manipulations were carried out by standard methods and using E. coli DH5α (Invitrogen)
as primary cloning host (124). All PCR-generated DNA fragments used in plasmid constructions
were sequenced to verify fidelity. The plasmids used in this study are listed in Table 2.
Genomic DNA isolation and plasmid electroporation into mycobacteria were carried out as
reported (123). Molecular biology reagents were obtained from Sigma, Invitrogen, Novagen, or
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Qiagen. The oligonucleotides used in this study are listed in Table 3 and Table 4, and they were
purchased from Integrated DNA Technologies, Inc. Solvents and non-radiolabeled chemicals
were purchased from Sigma, Acros Organics, or Fisher Scientific. [1-14C] propionate
(sp act = 54 mCi mmol-1) and [carboxyl-14C] p-hydroxybenzoic acid (sp act = 55 mCi mmol-1)
were acquired from American Radiolabeled Chemicals, Inc.
Construction of mycobacterial mutants.

The mutants were engineered using the

p2NIL/pGOAL19-based flexible cassette method(125) as reported (87,89,93). A gene-specific
mutagenesis-cassette delivery vector (see below) was used to construct each mutant. Each vector
was electroporated into Mm and the transformants with a potential single-crossover (blue
colonies) were selected on supplemented 7H11 containing hygromycin, kanamycin, and X-gal.
Potential single crossover-bearing clones were grown in antibiotic-free, supplemented 7H9, and
then plated for single colonies on supplemented 7H11 containing sucrose and X-gal. White
colonies that grew on sucrose plates were re-streaked onto antibiotic-free and antibioticcontaining plates to identify drug sensitive clones, a trait indicating a possible double-crossover
event with consequent allelic replacement or reversion to wild-type (wt). Gene deletions were
confirmed by PCR. For PCR analysis, genomic DNA from mutant candidates was used as
template along with two independent mutant-specific primer pairs (Table 3) to produce
amplicons permitting differentiation between mutant and wt genotypes based on amplicon size
(Figure 7). Nucleotide substitutions in the Mm ppsAS-to-A mutant were confirmed by DNA
sequencing. The mutated region was PCR-amplified with specific primers (Table 4) and the
resulting amplicon was sequenced (Figure 7 C)
Construction of mutagenesis-cassette delivery vectors. The following mutagenesiscassette delivery vectors were construed: p2NILGOALc-ΔfadD22c, carrying a fadD22
(MMAR_1761) deletion cassette (ΔfadD22c); p2NILGOALc-ΔfadD26c, carrying a fadD26
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(MMAR_1777) deletion cassette (ΔfadD26c); p2NILGOALc-ΔfadD28c, carrying a fadD28
(MMAR_1765) deletion cassette (ΔfadD28c); p2NILGOALc-ΔfadD29c, carrying a fadD29
(MMAR_1759) deletion cassette (ΔfadD29c); and p2NILGOALc-ppsAc, carrying a ppsA
(MMAR_1776) mutagenesis cassette (ppsAc) (see Figure 6 and Table 1). Each cassette was
constructed by joining a 5' arm and a 3' arm using splicing by overlap extension (SOE)
PCR(126). The primers and amplicon sizes are shown in Table 3. Each PCR-generated cassette
was first cloned into pCR2.1-TOPO (Invitrogen), verified for sequence fidelity, and then
subcloned into p2NIL (125). The cassettes ΔfadD22c, ΔfadD26c, ΔfadD28c, ΔfadD29c, and
ppsAc were cloned into p2NIL as SalI-NotI, HindIII-KpnI, BamHI-NotI, HindIII-PmlI, and
HindIII-HpaII fragments, respectively. Each resulting p2NIL-mutagenesis cassette construct and
the plasmid pGOAL19 (125) were digested with PacI, and then the PacI fragment with the
marker cassette (GOALc) of pGOAL19 was ligated to the p2NIL construct backbones to
generate the final delivery vectors. The configuration of each final cassette was as follows:
ΔfadD22c = fadD22’s 1,000-bp upstream segment + fadD22’s first 2 codons + fadD22’s last 2
coding codons + stop codon + 983-bp downstream segment; ΔfadD26c = fadD26’s 962-bp
upstream segment + fadD26’s first 5 codons + fadD26’s last coding 3 codons + stop codon +
929-bp downstream segment; ΔfadD28c = fadD28’s 947-bp upstream segment + fadD28’s first 5
codons + fadD28’s last 4 coding codons + stop codon + 935-bp downstream segment; ΔfadD29c
= fadD29’s 947-bp upstream segment + fadD29’s first 4 codons + fadD29’s last 5 coding codons
+ stop codon + 976-bp downstream segment; ppsAc = 1,832-bp segment with Ser-to-Ala
substitution mutations in the center.
Construction of pCP0 derivatives.

Plasmids pCP0-FadD22, pCP0-FadD26, pCP0-

FadD28, pCP0-FadD29, and pCP0-PpsA expressing FadD22, FadD26, FadD28, FadD29 and
PpsA, respectively, were constructed using the vector pCP0 (89).
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DNA fragments each

encompassing a Mm gene and its predicted ribosome-binding site were PCR-generated using
primer pairs shown in Table 4. The fragments were first cloned into pCR2.1-TOPO, verified for
sequence fidelity, and then subcloned into pCP0. The fadD22, fadD26, fadD28, fadD29, and
ppsA fragments were cloned into pCP0 as HindIII-HpaI, EcoRI-HindIII, NheI-HindIII, EcoRIHindIII, and HpaI-NheI inserts, respectively.
Analysis of PGLs and PDIMs. Four day old cultures were diluted to an OD595 nm of 0.6
in supplemented 7H9 and loaded into 12-well plates (1 ml per well). [14C]Propionate (labels
both PDIMs and PGLs) or [14C] p-hydroxybenzoic acid (selectively labels PGLs) was added to
each well (0.2 μCi ml-1) and the plates were incubated for 24 h (30°C, 170 rpm).

After

incubation, the OD595 nm of the cultures was measured in a plate reader (Beckman Coulter, Inc.)
and the cells were harvested for apolar lipid fraction extraction with a biphasic mixture of
methanolic saline and petroleum ether as reported (87,92). Lipid extracts were subjected to
radio-TLC for analysis of [14C]-labeled PGLs and [14C]-labeled PDIMs as described earlier
(87,92). Developed TLC plates were exposed to phosphor screens, which were scanned using a
Cyclone Plus Storage Phosphor System (PerkinElmer, Inc.).
RESULTS
A functional ACPL domain in PpsA is required for production of both PGLs and PDIMs in
M. marinum.
The ACPL domain of PpsA requires phosphopantetheinylation of the Ser residue embedded in
the P-pant group attachment site motif (NCBI CDD pfam00550/smart00823) of the domain to
become functional (127,128). Phosphopantetheinylation of the ACPL domain introduces the Ppant group onto which the fatty acids are loaded with assistance of the fatty acyl-AMP ligase
FadD26 to form the fatty acyl-ACPL domain thioester intermediate required for PDIM
biosynthesis in M. tuberculosis (86,96). Formation of the analogous PHPA-ACPL domain
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thioester intermediate would be required for PGL production in M. marinum if the Pks15/1-toPpsA PHPA intermediate transfer takes place by the PHPA-AMP ligase-dependent pathway
outlined in Figure 5 (pathway A). On the other hand, formation of the PHPA-ACPL domain
intermediate would not be needed for PGL production if the intermediate transfer proceeds via
direct capture by the KS domain of PpsA as depicted in Figure 5 (pathway B). With these
considerations in mind, we probed the essentiality of the P-pant group attachment site of the
ACPL domain of PpsA for PGL production by mutational analysis in M. marinum. To this end,
we engineered an unmarked, site-directed mutant (M. marinum ppsAS-to-A) with a Ser-to-Ala
substitution that eliminated the phosphopantetheinylation site (Ser43) in the ACPL domain of the
synthase. We identified Ser43 as the phosphopantetheinylation target in the P-pant group
attachment site sequence motif of the ACPL domain of PpsA by sequence analysis. The M.
marinum ppsAS-to-A mutant carried also a Ser42-to-Ala substitution. Ser42 (adjacent to Ser43)
was substituted in case it could become a surrogate phosphopantetheinylation target in the
absence of Ser43, a potentially confounding scenario.
Evaluation of PGL production in the M. marinum ppsAS-to-A mutant by radiometric-thin
layer chromatography (radio-TLC) analysis revealed that the strain was PGL deficient (Figure 8;
cf. lanes 1 and 2). Radio-TLC analysis revealed that the mutant strain was also unable to produce
PDIMs (Figure 8; cf. lanes 1 and 2), a result in line with previous biochemical studies on PDIM
biosynthesis in M. tuberculosis (86,96). Introduction of the plasmid pCP0-PpsA (expressing M.
marinum PpsA) into M. marinum ppsAS-to-A restored the capacity of the mutant to produce both
PGLs (Figure 8; cf. lanes 2 and 3) and PDIMs (Figure 8; cf. lanes 2 and 3).
Mutational analysis in M. marinum identifies FadD29 as a PHPA-AMP ligase candidate.
To seek further support for the mechanistic model proposed in pathway A (Fig. 3), we
undertook a systematic mutational analysis to conclusively establish the involvement of fadD22,
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fadD26, fadD28 and fadD29 in PGL and PDIM production in M. marinum and inform the
identification of a PHPA-AMP ligase candidate in a nontuberculous mycobacterial species. To
our knowledge, the involvement of M. marinum fadD22 and M. marinum fadD29 in production
of PDIMs and PGLs has not been probed by mutational analysis. M. marinum mutants with
transposon insertions in fadD26 and fadD28 were recently shown to have defects in PGL and
PDIM production, but potentially confounding polar effects produced by the transposon on other
genes of the pathway (Figure 4) preclude unequivocal gene-to-function assignments (100). To
conclusively probe the involvement of these M. marinum acyl-AMP ligases in PGL and PDIM
production, we engineered four mutants (M. marinum ΔfadD22, M. marinum ΔfadD26, M.
marinum ΔfadD28, and M. marinum ΔfadD29), each with an unmarked, in-frame deletion in
each of the four acyl-AMP ligase genes, and then examined the ability of the mutants to produce
PGLs and PDIMs by radio-TLC analysis.
The analysis of the PGL and PDIM production capacity of the fadD gene mutants
revealed that deletion of fadD28 led to a PGLˉ PDIMˉ phenotype (Figure 9; cf. lanes 5a and 6a
and cf. lanes 5b and 6b), deletion of fadD26 produced selective loss of PDIMs (Figure 9; cf.
lanes 1a and 4a and cf. lanes 1b and 3b), and deletion of fadD22 and fadD29 led to selective loss
of PGLs (Figure 9; cf. lanes 5a and 8a and cf. lanes 5b and 8b). We also constructed and
analyzed four corresponding genetic complementation control strains (M. marinum ΔfadD22 +
pCP0-fadD22, M. marinum ΔfadD26 + pCP0-fadD26, M. marinum ΔfadD28 + pCP0-fadD28,
and M. marinum ΔfadD29 + pCP0-fadD29). Each of these control strains carried a pCP0-based
plasmid expressing the specific fadD gene deleted from the genome of the host strain. RadioTLC analysis demonstrated that episomal expression of the fadD gene reasonably restored (fully
or partially) the PGL and/or PDIM production capacity of each of the M. marinum mutants
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(Figure 9; lanes 3a, 7a, 9a, 4b, and 7b). The complementation controls indicate that none of the
deletions exerted a confounding polar effect precluding fadD gene functional assignments.
CONCLUSIONS
We hypothesized two possible pathways by which this PHPA intermediate transfer could
take place in M. marinum (Figure 5). In one of these pathways (Figure 5, pathway A, steps A1A4), the intermediates would be first released from the phosphopantetheinyl (P-pant) group of
the acyl carrier protein (ACP) domain of Pks15/1 (step A1), and subsequently activated (step
A2) and loaded (step A3) by a dedicated PHPA-AMP ligase onto the P-pant group of the ACPL
domain of PpsA. The PHPA intermediates bound to the ACPL would be subsequently captured
by the ketosynthase (KS) domain (step A4) to generate the loaded PpsA (Figure 5, boxed acylPpsA species) ready for KS domain-dependent decarboxylation/condensation. The Pks15/1-toPpsA PHPA intermediate transfer mechanism represented in pathway A (Figure 5) emerges from
analogy to the fatty acyl-AMP ligase-dependent mechanism of fatty acid activation and loading
onto the ACPL domain of PpsA during PDIM biosynthesis in M. tuberculosis (86). Pathway A is
further supported by recent studies in the M. tuberculosis complex leading to the proposal that
the conserved fatty acyl ligase FadD29 (Figure 4) loads PHPAs onto PpsA (88), yet this idea
remains to be experimentally validated.
Notably, pathway A (Figure 5) requires free PHPA intermediates (step A1), yet sequence
analysis of Pks15/1 orthologs does not reveal the presence of a possible thioesterase domain that
would conveniently catalyze the release of the PHPA intermediates thioesterified to the P-pant
group of the ACP domain of the synthase (78,95). This does not rule out, however, the
possibility that the PHPA intermediates are released without the assistance of an external (selfstanding) thioesterase or by the action of one. In the latter option, the thioesterase could be TesA,
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which is encoded in the PGL/PDIM biosynthetic gene cluster (Figure 4) and was recently shown
to be required for PGL and PDIM production in M. marinum (89,115).
In the second possible pathway for Pks15/1-to-PpsA PHPA intermediate transfer in M.
marinum (Figure 5, pathway B), the PHPAs thioesterified to the P-pant group of the ACP
domain of Pks15/1 would be directly captured by the KS domain of PpsA (step B1), thus
bypassing the need for steps A1-A4. This direct Pks15/1-to-PpsA chain translocation would
“skip” the ACPL domain of PpsA. Domain skipping has in fact been demonstrated in a few PKS
systems (129,130). Moreover, this direct capture pathway would have adaptive value because it
would not require ATP for PHPA intermediate activation, an essential step in pathway A (step
A2). This pathway would also obviate the need to off-load the PHPA intermediates from the
ACP domain of Pks15/1 (pathway A, step A1). Overall, the findings of the mutational analysis in
M. marinum are in line with the idea that the Pks15/1-to-PpsA PHPA intermediate transfer takes
place by the PHPA-AMP ligase-dependent pathway outlined in pathway A of Figure 5. The
results also suggest that direct capture of the PHPA intermediates thioesterified to the ACP
domain of Pks15/1 by the KS domain of PpsA (Figure 5, pathway B) is not a transfer mechanism
of physiological relevance in M. marinum.
The mechanistic model proposed in pathway A (Figure 5) includes an acyl-AMP ligase
competent to activate and load the PHPA intermediates onto the ACPL domain of M. marinum
PpsA (steps A2 and A3, respectively).

Aside from the p-hydroxybenzoic acid-specific

adenylation domain of M. marinum FadD22 (87,95), there are three conserved acyl-AMP ligases
encoded in the PGL/PDIM biosynthetic gene cluster, i.e., FadD26, FadD28 and FadD29
(65,78,81,85,86,96) (Figure 4). Recent studies in the M. tuberculosis complex have led to the
proposal that FadD29 adenylates and loads PHPAs onto PpsA in M. tuberculosis (88), but the
idea has not been experimentally explored. Overall, the findings of the mutational analysis of
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fadD genes conclusively demonstrate the specific roles of fadD22, fadD26, fadD28, and fadD29
in PGL and/or PDIM production in M. marinum. These studies in conjunction with the
biochemical information available for M. marinum FadD22 (87,95) point at M. marinum FadD29
as the likely PHPA-specific AMP ligase involved in PHPA intermediate activation and loading
onto PpsA in M. marinum. They also parallel the conclusions derived from experiments in the M.
tuberculosis complex (84,87,88). To the best of our knowledge this is the first study in M.
marinum, nontuberculous mycobacterium, which supports the role of FadD29 ligase in the
transfer of the PHPA intermediates from the iterative polyketide synthase system (PKS 15/1) to
the non-iterative system (PpsA) during PGL synthesis.
The mutational studies reported herein are supported by in vitro enzymatic studies
conducted on the M. marinum FadD29-PpsA functional partnership (1), which represents the
first acyl-AMP ligase and type I PKS partnership for acyl starter unit activation and PKS loading
established in a nontuberculous mycobacteria. Three analogous partnerships have been
demonstrated in M. tuberculosis. These are the FadD26-PpsA partnership noted above for PDIM
production (86,96), a FadD32-Pks13 partnership that takes place during mycolic acid
biosynthesis (86,131,132), and a FadD30-Pks6 partnership believed to be required for production
of novel polar lipids (86), (91).To our knowledge, however, the partially overlapping PGL/PDIM
biosynthetic pathways provide the first example of two distinct acyl-AMP ligases (i.e., FadD29
and FadD26) loading the same type I PKS (i.e., PpsA) with two alternate starter units (i.e.,
PHPAs and fatty acids). This bimodal loading strategy allows the bacterium to use the
PpsABCDE megasynthase system to generate two structurally different products. Interestingly,
recent host-pathogen interaction studies suggest that M. marinum PGLs and M. marinum PDIMs
have different roles within a complex immune evasion mechanism (110). It will be interesting to
investigate whether the FadD29-PpsA versus FadD26-PpsA alternative partnership is utilized by
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the pathogen as a control point to modulate the relative abundance of PGLs and PDIMs in the
cell.
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CHAPTER 3: PLEIOTROPIC CONSEQUENCES OF GENE KNOCKOUTS IN THE
PHTHIOCEROL DIMYCOCEROSATE AND PHENOLIC GLYCOLIPID
BIOSYNTHETIC GENE CLUSTER OF MYCOBACTERIUM MARINUM
INTRODUCTION
Numerous studies support the view that the unique mycobacterial (glyco)lipids PDIMs
and PGLs and their related congeners (Figure 3) are involved in pathogenicity through intricate
and incompletely understood mechanisms (105). Notably, recent studies suggest complementary
roles of PDIMs and PGLs in a complex immune evasion mechanism that leads to avoidance of
microbicidal macrophages and preferential recruitment and infection of permissive ones (110).
There is also evidence supporting the notion that, at least in some species, some of these lipids
strengthen the cell envelope permeability barrier (82,100) and can increase the bacterium’s
intrinsic resistance to antimicrobial drugs (89,100,115).
The relevance of PDIMs and PGLs in the biology of several pathogenic mycobacteria
highlights the biosynthesis of these unique virulence factors as an attractive target for exploring
the development of antivirulence drugs that might be useful in adjuvant chemotherapeutic
approaches. This consideration has provided thrust for numerous studies directed towards the
elucidation of the PDIM/PGL biosynthetic pathway. These studies have led to the identification
of several conserved genes required for production of PDIMs and/or PGLs and to the elucidation
of the specific roles that several of these genes play in the pathway (65). The knowledge gained
from some of these studies has guided the rational design of the first inhibitor of PGL
biosynthesis (87). The inhibitor specifically targets a conserved p-hydroxybenzoic acid
adenylating enzyme (FadD22) essential for PGL synthesis and has potent activity in members of
the M. tuberculosis complex and in nontuberculous mycobacterial pathogens, such as M.
marinum (87,95). Studies with M. marinum mutants deficient in PDIM and/or PGL production
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have revealed that both PDIMs and PGLs are required for virulence in the zebrafish (Danio
rerio) model system (100,110,115).
We recently reported mutational studies with M. marinum that interrogated the
involvement of the genes tesA, papA5, fadD22, fadD26, fadD28, and fadD29 in production of
PDIMs and PGLs (1,89). These six genes are conserved in M. tuberculosis and other PDIM and
PGL producers (Figure 4) (78).The studies based on gene-specific, unmarked deletion mutants,
revealed that the ∆tesA, ∆papA5, and ∆fadD28 mutants are PDIMˉ PGLˉ, the ∆fadD22 and
∆fadD29 mutants are PDIM+ PGLˉ, and the ∆fadD26 mutant is PDIMˉ PGL+. Each (glyco)lipid
deficiency was complemented by episomal expression of a wild-type (WT) copy of the deleted
gene, thus permitting unambiguous genotype-to-phenotype assignments. Overall, these findings
are in line with those from other studies (100,115). The proposed function of tesA, papA5,
fadD22, fadD26, fadD28, and fadD29 in PDIM and/or PGL synthesis is outlined in Table 6 and
(65).
In the current study, we utilized the available array of well-defined deletion mutants of
M. marinum noted above to further interrogate the phenotypic consequence of each of the six
gene knockouts. In particular, the parallel analysis of these mutants permitted us to begin
exploring the hypothesis that different gene knockouts in the complex PDIM/PGL biosynthetic
pathway that render the same PDIM and/or PGL deficiency lead to mutants with equivalent
pleiotropic phenotype profiles. Exploration of this hypothesis is relevant in the context of
considering specific enzymes of the pathway as potential targets for exploring the development
of antivirulence drugs that might be useful in adjuvant chemotherapeutic approaches against
mycobacterial infections.
We evaluated the M. marinum mutants in assays to probe for changes of cell surface
properties, cell envelope permeability, drug susceptibility, biofilm formation, sliding motility or
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growth in vitro. We also explored the relative virulence of the mutants using an assay developed
with Dictyostelium discoideum, a phagocytic amoeba established as a model unicellular
organism to study host-pathogen interactions with several pathogens, including M. marinum
(133,134). Overall, the results presented herein illustrate the complexity of the phenotypic
implications arising from different gene knockouts in the PDIM/PGL biosynthetic gene cluster
and expose unexpected phenotypic inequalities, a finding with potential implications in the
context of antivirulence drug target considerations.
MATERIALS AND METHODS
Strains and routine culturing conditions. Mycobacteria (Table 5) were cultured under
standard conditions in Middlebrook 7H9 basal medium (Difco, BD Biosciences) supplemented
with 10% ADN (5% BSA, 2% dextrose, 0.85% NaCl) (Difco, BD Biosciences), 0.05% Tween80, and 0.2% glycerol (supplemented 7H9) or Middlebrook 7H11 basal medium (Difco, BD
Biosciences) supplemented with 10% ADN (supplemented 7H11) (123). Kanamycin (30 μg/ml)
was included in the growth media for maintenance of pCP0 plasmids. M. marinum WT and the
M. marinum mutants carried the vector pCP0 so that they could be cultured in the same
kanamycin-containing media used for the complementation control strains carrying pCP0
expressing a WT copy of the gene deleted from the chromosome. D. discoideum DH1-10 (135)
was axenically cultured under standard conditions in supplemented HL5 medium (ForMedium
Co. Ltd.) at 25˚C with orbital shaking (170 rpm) (136).
Congo red binding. Plates of supplemented or nonsupplemented 7H11 medium without
or with 100 µg/ml of Congo red (Sigma Aldrich Co.) as reported (137) were spot-inoculated with
2 µl of mycobacterial cultures grown to saturation in supplemented 7H9 medium. The inoculated
plates were incubated at 30°C under a humidified atmosphere for 2 weeks (supplemented plates)
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or 4 weeks (nonsupplemented plates). After incubation, mycobacterial colonies were imaged
using an Olympus SZX7 stereo microscope (Olympus Corp.).
Ethidium bromide accumulation.

Assay conditions were guided by previously

published protocols (100,138,139). Mycobacterial cells from cultures grown to exponential
phase in supplemented 7H9 medium were harvested by centrifugation, resuspended in of 50 mM
phosphate-buffered solution, pH 7 (PBS, 1 × culture vol), and collected again by centrifugation.
The PBS-washed cells were resuspended in PBS (1 × culture vol), and the suspension was
loaded into black, flat-bottom, 96-well plates (Greiner Bio-One Co.) at 152 μl/well. Following
loading, 8 μl of a 10% glucose solution in PBS were added to the wells and the plates were
incubated for 5 min at 25°C. After incubation, 40 μl of an ethidium bromide (EtBr) solution in
PBS (25 mg/l) were added to the wells and fluorescence intensity (535 nm excitation, 595 nm
emission) was measure every 90 seconds for 30 min using a plate reader (DTX 880 Multimode
Detector, Beckman Coulter, Inc.). Initial EtBr accumulation rates were determined as the slope
of the linear regression line fitted to datasets of normalized relative fluorescence units [nRFU =
(RFUt=x-RFUt=o)/OD595] versus time using the program Microsoft Excel (Microsoft Corp.).
Antibiotic susceptibility.

Dose-response studies were conducted using a standard

microdilution method previously reported (89,140). Cultures grown to exponential growth phase
in supplemented 7H9 medium were diluted in fresh medium to an OD595 of 0.005 and loaded
into 96-well plates (200 μl/well). Rifampicin (EMD-Calbiochem), doxycycline (Sigma-Aldrich
Co. LLC), and erythromycin (Sigma-Aldrich Co. LLC) were added to the medium from stock
solutions in dimethyl sulfoxide (DMSO; Sigma-Aldrich Co. LLC). Cefuroxime (Sigma-Aldrich
Co. LLC), ciprofloxacin (Fluka-Biochemika) and streptomycin (Sigma-Aldrich Co. LLC) were
added from aqueous solutions. In the former case, DMSO was kept at 0.5% in both test and
control wells. Plates were incubated at 30°C with orbital shaking (170 rpm) under a humidified
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atmosphere for 8 days. After incubation, growth was assessed by measuring OD595 using a plate
reader. MIC values for fold-change determinations were calculated from sigmoidal curves fitted
to dose-response datasets using the program GraphPad Prism (GraphPad Software, Inc.) as
reported (141,142).
Biofilm formation. Mycobacterial cells from exponential growth phase cultures diluted
to 1 × 106 CFU/ml in 7H9 basal medium supplemented with 0.2% glycerol were loaded (150
μl/well) into MBEC plates (143,144). After loading, the plates were covered with their 96-peg
lids, and incubated at 30°C with gentle agitation (100 rpm) under a humidified atmosphere for 4
weeks. Biofilm formation on the pegs was quantified using a standard crystal violet-based
colorimetric method (145,146). Briefly, the pegs were immersed in a 0.5% crystal violet solution
(150 μl/well in a 96-well receiver plate) for 15 min, rinsed twice with distilled water, and
allowed to air dry. Stained pegs were then immersed in 95% ethanol (150 μl) using a 96-well
receiver plate and agitated (100 rpm) for 1 h for dye extraction. The 96-peg lids were then
removed, allowed to air dry, and the biofilms on the pegs were imaged using an Olympus SZX7
stereo microscope and an Olympus BX41 compound microscope. Absorbance of the decolorizing ethanol solution was measured at 595 nm using a plate reader. Pellicle formation was
investigated using a multiwell plate-based assay similar to those reported (137,147,148). Wells
of 24-well plates preloaded with Sauton’s medium (without Tween 80; 1 ml/well) were
inoculated at the liquid surface with 10 µl of saturated mycobacterial cultures and the plates were
incubated at 30°C under stationary conditions and a humidified atmosphere for 5 weeks. After
incubation, the pellicles were imaged using an Olympus SZX7 stereo microscope.
Sliding motility. Cultures grown to exponential growth phase in supplemented 7H9
medium were spotted (5 μl) on the center of sliding motility plates (7H9 basal medium, 0.3% or
0.5% high-grade agarose, 6 % glycerol; 25 ml of medium/Petri dish) (137,149,150). Inoculated
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plates were incubated at 30°C under a humidified atmosphere (12 days and 14 days for 0.3% and
0.5% agarose plates, respectively). After incubation, sliding motility was determined as the
average diameter of the spreading zone as reported (137).
In vitro growth.

The experiments were conducted using a 96-well plate platform

previously reported (89). The plates were loaded with supplemented 7H9 medium inoculated
with late exponential growth phase cultures (200 μl/well; OD595 = 0.005) and incubated at 30°C
with orbital shaking (170 rpm) under a humidified atmosphere for 14 days. Growth was assessed
every 24 hours by measuring the OD595 of the cultures using a plate reader. Maximum specific
growth rate (µm) values and the optical density plateau values reached at stationary phase were
determined for each of three independent experiments from sigmoidal growth curves fitted with
the modified Gompertz equation using the program GraphPad Prism (151).
D. discoideum experiments. The amoeba inhibition assay was a variation from an assay
recently published (115). Briefly, a Mycobacterium-Klebsiella aerogenes mixture (50 µl)
prepared as reported (115) was used to surface-inoculate wells of 24-well plates containing 2 ml
of 7H10 agar (Difco, BD Biosciences) to generate bacterial lawns. After inoculation with the
bacterial mixture, the wells were spot-inoculated (5 µl) in the center with 2-fold serial dilutions
(2 × 103 to 3×107 cells/ml range) of a D. discoideum culture. Plates were then incubated for 14
days at 25°C under a humidified atmosphere. Starting on the third day of incubation, wells were
visually inspected daily for formation of phagocytic plaques for 10 days. D. discoideum growth
was defined for any given set of duplicates wells (same amoeba inoculum) that exhibited at least
two phagocytic plaques in each of the wells.
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RESULTS
Gene knockouts in the PDIM/PGL biosynthetic pathway alter cell surface properties.
Mutations producing changes in the composition of the (glyco)lipid-rich outer layer of
the waxy mycobacterial cell envelope can potentially lead to differences in the binding of the
hydrophobic dye Congo red (CR) (152). Guided by this precedent, we investigated the CR
binding properties of the tesA, papA5, fadD22, fadD26, fadD28, and fadD29 M. marinum
mutants (Figure 10). On supplemented 7H11 plates, the mutants and the WT developed the same
reddish coloration in the presence of CR, thus indicating comparable CR binding properties. On
the other hand, the mutants displayed a drastic increase in CR staining relative to the WT on
nonsupplemented 7H11 plates, where mycobacteria grow under stress due to the lack of the
protective and growth-stimulating effect of the ADN and glycerol supplements (153,154).
Episomal expression in the mutants of a WT copy of the deleted gene led to clear
complementation (reversion to WT CR staining) only in the tesA and fadD28 mutants, despite
the fact that all the genetically complemented mutants regain the capacity for PDIM and/or PGL
production (1,89,92). Overall, the results clearly indicate that the gene knockouts affect cell
surface properties and highlight the fact that the outcome of a CR binding assay can be
drastically influenced by growth medium composition.
Gene knockouts in the PDIM/PGL biosynthetic pathway weaken the cell envelope
permeability barrier.
Mutations that alter cell surface properties may affect cell envelope permeability as well.
In agreement with this view, previous studies revealed that a transposon insertion-based
disruption of fadD28 or fadD26 in M. marinum leads to a comparable increase in cell envelope
permeability (100).

Disruption of fadD26 (leading to PDIMˉ) in the strain MT103 of M.
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tuberculosis (a strain naturally PGLˉ) also results in an increase in cell envelope permeability
(82). These previous studies are consistent with the notion that abrogation of PDIM production
weakens the cell envelope permeability barrier. However, these studies provide no information
as to whether gene knockouts leading to the selective loss of PGLs affect cell envelope
permeability. To address this knowledge gap and to expand our overall understanding of the
impact of inactivating different genes required for PDIM and/or PGL production on cell
envelope permeability, we investigated the EtBr accumulation rates of the M. marinum deletion
mutants. EtBr accumulation assays are routinely used to probe cell envelope permeability in
bacteria, including mycobacteria (100,138,139). Using this approach, we found that each gene
knockout correlated with an increase in EtBr accumulation rate compared to M. marinum WT
and the corresponding complemented strain control (Figure 11). Interestingly, knockouts leading
to concurrent loss of PDIMs and PGLs or selective loss of PDIMs roughly doubled the rate,
whereas knockouts selectively eliminating PGLs produced a 25% increase. To the best of our
knowledge, this is the first study linking loss of PGLs with a weakening of the cell envelope
permeability barrier. Overall, these results are consistent with the view that PDIMs have a more
relevant role in the integrity of the cell envelope permeability barrier of M. marinum than PGLs.
Gene knockouts in the PDIM/PGL biosynthetic pathway increase antimicrobial drug
susceptibility.
Mutations leading to a weakening of the cell envelope permeability barrier can
potentially increase antimicrobial drug susceptibility by improving drug penetration.

In

agreement with this notion, we and others have recently shown that inactivation of tesA in M.
marinum leads to hypersusceptibility to various antimicrobial drugs (89,115). To expand on this
observation, we investigated the susceptibility of the M. marinum mutants to antimicrobial drugs
of different classes.

The group of six drugs tested included rifampicin, doxycycline,
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ciprofloxacin and streptomycin, which are four drugs with reported use in the treatment of M.
marinum infections (155).

In this analysis, a strain was defined as having an altered

susceptibility when it displayed >2-fold change in the MIC value relative to the MIC value of the
WT strain (Figure 12). As per this criterion, and in general agreement with previous studies
(89,115), the tesA mutant showed hypersusceptibility to cefuroxime, doxycycline, rifampicin and
erythromycin, but not to ciprofloxacin or streptomycin.

This susceptibility profile was

qualitatively and quantitatively recapitulated in the papA5 mutant. On the other hand, the
fadD28, fadD26, fadD22 and fadD29 mutants displayed hypersusceptibility profiles that, for the
most part, were qualitatively comparable, yet quantitatively attenuated relative to that of the tesA
and papA5 mutants. The attenuated hypersusceptibility profile of the fadD28 mutant is
particularly unexpected because the mutant shares the PDIMˉ PGLˉ phenotype with the tesA and
papA5 mutants and has an increase in cell permeability comparable to that of these mutants.
Episomal expression in the mutants of a WT copy of the corresponding deleted gene flattened
the hypersusceptibility profiles and, in all, decreased or eliminated the hypersusceptibility of the
mutants. In line with our findings, transposon insertion-based disruption of fadD26 or fadD28 in
M. marinum correlates with increased drug susceptibility (100). Taken together, the results
indicate that only two out of three knockouts producing concurrent loss of PDIMs and PGLs lead
to a drastic increase in susceptibility to selective drugs and that mutations resulting in a selective
loss of PDIMs or PGLs affect drug susceptibility to a lesser extent.
Gene knockouts in the PDIM/PGL biosynthetic pathway are detrimental to biofilm
formation.
Recent studies implicated the M. marinum cell wall-associated glycolipids known as
lipooligosaccharides (LOSs) in formation of biofilms (149). This raises the possibility that other
cell wall (glyco)lipids of M. marinum could be relevant for biofilm formation. With this in
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mind, we explored the capacity of the M. marinum mutants to form biofilms on solid and liquid
surfaces. Biofilm formation on a solid surface was investigated using the MBEC plates (144),
which consists of a standard 96-well plate with a lid containing 96 polystyrene pegs that fit into
the wells and on which M. marinum forms biofilms (156,157).

In line with previous

observations, M. marinum WT formed biofilms on the pegs (Figure 13 A) and the biofilm
microcolonies displayed the characteristic serpentine cords (Figure 13 B) (156,157). The mutants
also formed biofilms, but they displayed smaller and/or less abundant microcolonies on the pegs
(Figure 13 B) and less biofilm formation overall (32-80% reduction relative to WT) (Figure 13
C). Notably, the tesA, papA5, and fadD26 knockouts led also to more compact cell aggregates
with reduced cording (Figure 13). Episomal expression in the mutants of a WT copy of the
deleted gene increased biofilm formation and corrected the cording deficiency.
Formation of biofilms on a liquid surface (pellicle formation) was evaluated using a
multiwell plate-based assay, a set-up developed for evaluation of pellicle formation by other
mycobacteria (137,147,148). We found an equally robust pellicle formation capacity for the WT
and the mutants. No differences in pellicle surface topology between the strains that could
consistently be maintained across experimental replicates were observed under our experimental
conditions. Overall, all pellicles showed a comparably rich surface topology with folds, ridges,
and creases (Figure 13).
Overall, the findings of the biofilm studies demonstrate that the knockouts leading to loss
of PDIMs and/or PGLs produced a reduction in the capacity of M. marinum to form biofilms on
a solid surface, but had no evident impact on pellicle formation. To the best of our knowledge,
this is the first study indicating that loss of PDIM and/or PGL production affects biofilm
formation.
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Gene knockouts in the PDIM/PGL biosynthetic pathway have no evident impact on sliding
motility.
Mycobacteria can spread on the surface of solid media by a sliding mechanism, a
property that could have implications for surface colonization in the environment and in the host
(158). In M. marinum, LOSs have been implicated in sliding motility (149), thus raising the
possibility that other M. marinum cell wall (glyco)lipids could be relevant for this motility
mechanism. We investigated the sliding motility capacity of the M. marinum mutants using a
standard assay in which the diameter of the spreading zone provides a quantitative read-out of
sliding (data not shown). We found that all the strains had sliding motility capacity, albeit with
relatively high variability between experimental replicates. Overall, no significant differences
were observed between the mutants and the WT (Student’s t-test p values > 0.05; data not
shown). Thus, neither PDIMs nor PGLs play a critical role in sliding motility.
Gene knockouts in the PDIM/PGL biosynthetic pathway do not compromise in vitro
growth.
To delineate the effect of different gene knockouts in the PDIM/PGL pathway on M.
marinum growth in vitro, we compared the mutants and the WT strain on the basis of two
quantitative parameters derived from sigmoidal growth curves: i.e. maximum specific growth
rate (µm) and optical density plateau reached at stationary phase. Under standard liquid culture
conditions, no substantial differences (i.e. ≥10%) in µm or optical density plateau between the
mutants and the WT strain were observed (not shown). Overall, the results are in line with
previous studies with M. marinum ∆tesA (89).
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Gene knockouts in the PDIM/PGL biosynthetic pathway lead to attenuation in an amoeba
inhibition assay.
D. discoideum is a phagocytic, bacterium-eating amoeba used as a model unicellular
organism to study host-pathogen interaction and virulence of mycobacteria and other pathogens
(133,134). M. tuberculosis complex members and non-tuberculous mycobacterial pathogens such
as M. marinum are amoeba-resistant organisms that multiply intracellularly leading to amoeba
growth arrest and cytotoxicity (159-161). These pathogens compromise amoebal phagolysosome maturation and replicate inside permissive endosomal compartments, a pathogenic
strategy seen during macrophage infection (160,162).
A virulence assay based on M. marinum-dependent inhibition of D. discoideum was
recently used to identify a tesA transposon mutant as an attenuated strain (115). In this assay, D.
discoideum feeding and multiplying on a lawn of K. aerogenes (amoeba food) produce
phagocytic plaques, i.e. K. aerogenes lawn clearing zones.

Inclusion of M. marinum WT

intermingled into the K. aerogenes lawn leads to M. marinum infection and consequent
inhibition of D. discoideum, thus reducing phagocytic plaque formation. By comparison, the
attenuated tesA mutant has a diminished plaque formation suppression capacity (115). We
modified this assay to better differentiate virulence degrees between mycobacterial strains and
used the modified assay to probe the virulence of the M. marinum mutants (Figure 14). We
performed the assay in a 24-well plate platform, expanded the inoculum of amoeba cells to a 10to-150,000 range from the 100-to-10,000 range reported, and escalated the amoeba inoculum
using 2-fold increments, as opposed to the 10-fold increments used previously (115). The
phagocytic plaque formation read-out was used to score wells in a binary fashion: amoeba
growth versus amoeba inhibition. For each M. marinum strain, the highest amoeba inoculum
inhibited was considered a measure of the amoeba inhibition capacity of the strain. Using
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amoeba inhibition capacity as a quantitative measure of virulence, we found a drastic reduction
in virulence (~300-fold to ~500-fold relative to WT) for the tesA, papA5, fadD28, and fadD26
mutants. On the other hand, the fadD22 and fadD29 mutants exhibited a modest virulence
reduction (3-fold relative to WT). As expected, episomal expression of a WT copy of the deleted
gene increased the virulence of the mutants. Interestingly, even the most attenuated mutants
remained significantly more virulent than the nonpathogenic M. smegmatis species. Collectively,
these results indicate that gene deletions producing concurrent loss of PDIMs and PGLs or
selective loss of PDIMs lead to severe attenuation in the D. discoideum model system. In
contrast, gene deletions producing selective loss of PGLs are relatively inconsequential in this
amoeba model. These findings support the view that PDIMs have a more critical role in the
pathogenicity of M. marinum against D. discoideum than PGLs.
CONCLUSIONS
The basic lipid cores of PDIMs and PGLs arise from esterification of phthiocerols and
phenolphthiocerols, respectively, with mycocerosic acids (Figure 3). The current model for the
biosynthesis of these esters includes the conserved enzymes TesA, PapA5, FadD22, FadD26,
FadD28 and FadD29. The availability of a set of six M. marinum mutant strains that are isogenic
except for a defined unmarked deletion of tesA, papA5, fadD22, fadD26, fadD28, or fadD29,
respectively, provided an opportunity to comparatively probe for the pleiotropic consequences of
mutations leading to PDIMˉ PGLˉ, PDIM+ PGLˉ, or PDIMˉ PGL+ phenotypes in this
opportunistic human pathogen. Furthermore, the tesA, papA5 and fadD28 mutant triad permitted
us to explore whether M. marinum mutants with a PDIMˉ PGLˉ phenotype arising from different
genetic etiologies share other phenotypic traits. Similarly, the fadD22 and fadD29 mutant pair
allowed us to investigate whether strains with a PDIM+ PGLˉ phenotype emerging from different
gene knockouts are equivalent with respect to other phenotypes as well. Thus, the parallel
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analysis of the M. marinum mutants gave us an opportunity to begin exploring the hypothesis
that different gene knockouts in the complex PDIM/PGL biosynthetic pathway that render the
same PDIM and/or PGL deficiency lead to strains with equivalent pleiotropic profiles.
Exploration of this hypothesis is relevant in the contexts of considering specific enzymes of the
pathway as potential targets for exploring the development of antivirulence drugs that could be
useful in adjuvant chemotherapeutic approaches against mycobacterial infections.
Our studies reveal that loss of production of PDIMs or PGLs leads to an alteration of cell
envelope properties. In particular, our findings illustrate for the first time a link between loss of
PGL production and a weakening of the cell envelope permeability barrier and show that PGLs
are far less relevant to the integrity of such a barrier than PDIMs. The mutants also display
changes in antimicrobial drug susceptibility. The increased susceptibility in the mutants might be
due to better drug penetration arising from the weakening of the cell envelope permeability
barrier; yet the magnitude of the change in susceptibility appears to be drug-specific and
uncorrelated with the lipophilicity (e.g. log P (163)) of the drug. Our findings indicate that the
tesA and papA5 mutants (PDIMˉ PGLˉ) have the same hypersusceptibility profile and are overall
more susceptible than the fadD26 mutant or the fadD22 and fadD29 mutants, in which only
PDIMs or PGLs are lost, respectively. Intriguingly, the fadD28 mutant (PDIMˉ PGLˉ) shows a
relatively attenuated hypersusceptibility profile compared with that of the tesA and papA5
mutants. The fadD28 mutant differs from the tesA and papA5 mutants also in terms of biofilm
microcolony phenotype. The microcolonies of the fadD28 mutant retain the WT phenotype,
whereas those of the tesA and papA5 mutants form more compact cell aggregates with reduced
cording. Interestingly, the appearance of anomalous PDIM-like lipid variants with shorter
mycocerosic acid-like acyl chains has been documented in the mycocerosic acid-deficient mutant
of Mycobacterium bovis BCG (71,84,164). Perhaps production of anomalous lipid variants with
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surrogate acyl chains in the absence of mycocerosic acids due to deletion of fadD28 in M.
marinum ∆fadD28 is responsible for the attenuated hypersusceptibility profile of the mutant.
Overall, the findings of the antibiotic susceptibility studies support the exciting possibility that
antivirulence drug therapy aimed at blocking PDIM and PGL production might increase the
efficacy of some antimicrobial drug treatments and suggest that such an effect could be
drastically influenced by the molecular target of the antivirulence drug, e.g. PapA5 versus
FadD28.
Our studies also reveal that all the M. marinum mutants are attenuated in a D. discoideum
inhibition assay, albeit with clear differences in the degree of attenuation. We found that
concurrent loss of PDIMs and PGLs or selective loss of PDIMs has a far more drastic effect in
virulence than selective loss of PGLs. Mycobacterial pathogens are known to compromise
amoebal phagolysosome maturation to avoid killing and create niches for intracellular
replication, a pathogenic strategy seen during macrophage infection (160,162). In M.
tuberculosis, transposon-based disruption of fadD28 impairs the ability of the pathogen to arrest
phagolysosome maturation in macrophages (116), possibly by lacking PDIMs to elicit pathogendirected reorganization of lipid in the host membrane (107). This precedent highlights the
possibility that the attenuation of the M. marinum mutants might emerge from a reduced capacity
to arrest the amoebal phagolysosome maturation pathway and create protective niches.
Interestingly, even the most attenuated M. marinum mutant remains significantly more virulent
than the nonpathogenic M. smegmatis species. This observation indicates that M. marinum has
multiple virulence factors contributing to the interplay with the amoeba host. This notion is not
surprising considering that M. marinum and amoebae share environmental niches and that
amoebae are thought to act as evolutionary training grounds for intracellular bacterial pathogens
(165).
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Taken together, the results of the phenotypic characterization of M. marinum mutants
presented herein reveal a complex picture of pleiotropic patterns emerging from different gene
knockouts in the PDIM/PGL biosynthetic pathway. These pleiotropic patterns could be
influenced by changes in metabolic flux redirecting surpluses of different biosynthetic precursors
to production of other (glyco)lipids (87,103,104).

Accumulation of different biosynthetic

intermediates, some of which might be repurposed for production of unusual lipids with potential
phenotypic impacts, might also contribute to define the pleiotropic patterns displayed by the
different mutants (71,84,164). Ultimately, it is clear that (glyco)lipidomic profiling of the M.
marinum mutants will be needed to investigate these possibilities. Information from such studies
will be critical towards the challenging endeavor of unveiling the molecular mechanisms
underlying the phenotypic profiles of the different mutants.
Overall, the parallel analysis of the M. marinum mutants permitted us to uncover
unexpected phenotypic inequalities, a finding with potential implications in the context of
antivirulence drug target considerations. Most noticeably, the differences between the tesA,
papA5 and fadD28 knockouts, three events leading to a PDIMˉ PGLˉ phenotype, suggest that the
enzymes encoded by these genes might not be equivalent targets for development of
antivirulence drugs. In more general terms, our results advocate that different enzymes for
which elimination equally leads to PDIM and PGL deficiency might not be equivalent targets for
adjuvant drug development.
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CHAPTER 4: CONCLUDING REMARKS AND FUTURE DIRECTIONS
This thesis has provided cumulative evidence for the relevance of DIMs in the biology of
mycobacteria by presenting new mechanistic insights into their biosynthetic pathway and
elucidating their contribution to the phenotype of M. marinum. More specifically the work has
helped establish the relevance of the ACPL domain of PpsA in the extension of the PHPA
intermediates as well as the vital role of FadD29, in the transfer of the PHPA intermediates from
the iterative PKS Pks15/1 to the non-iterative PKS PpsA, during PGL biosynthesis. The results
from the mutational studies and the supporting in vitro enzymatic studies has not only provided
the first evidence of a PHPA-ligase candidate FadD29 within a nontuberculous mycobacterial
species but has also provided valuable insight into the partnership of FadD29-PpsA versus
FadD26-PpsA during PDIM and PGL biosynthesis, respectively. The conservation of the DIM
biosynthetic genes across the species strongly suggests that the mechanistic insights into PGL
biosynthesis gained herein are applicable to other PGL producers like members of the MTBC.
Taken together these results provide vital information to build the framework of DIM
biosynthesis in mycobacteria.
This thesis has also presented novel findings on the phenotypic consequences resulting
from PDIM and/or PGL deficiency in M. marinum and suggested that the loss of genes in the
same pathway alters the observed phenotypic output in different ways. The complex pleiotropic
patterns emerging from the different knockouts might be influenced by changes in metabolic flux
redirecting different biosynthetic precursor surpluses to the production of other (glyco)lipids
(87,103,104). Accumulation of different biosynthetic intermediates, some of which might be
repurposed for the production of unusual (glyco)lipids with potential phenotypic impacts (71,84),
might also contribute to define the pleiotropic patterns of the mutants seen here. Overall the
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pleiotropic changes reported here provide valuable information on the biology of mycobacteria
and can possibly relate to adaptations of the bacterium within the host during infection.
While we have made considerable strides in understanding the biosynthesis of DIMs and
their contributions to the phenotype of mycobacteria there are knowledge gaps that continue to
challenge the scientific community. A natural progression of this work will be to further clarify
the steps involved the biosynthesis of these lipids using genetic and biochemical studies. Another
possible area of research will be to elucidate the molecular mechanisms underlying the
phenotypic profiles of the DIM deficient mutants and the mechanisms surrounding the
modulation of PDIMs and PGLs during infection.

52

FIGURES

Figure 1: Schematic representation of the M. tuberculosis cell envelope.
Adapted from (51). Many of the classes of lipids and glycolipids discussed in the text are
represented schematically and are shown in probable locations in the cell envelope. The
structures with light and dark green hexagons represent trehalose mono- and dimycolates
respectively; the red lollipops represent phthiocerol dimycocerosates, and the gold ones represent
sulfolipids, diacyltrehaloses and polyacyltrehaloses. Gray circles represent phospholipid
headgroups; black circles. isoprenoids; light blue squares. NAG; white squares, NAM; white
pentagons, arabinofuranose; yellow diamonds, galactofuranose; and blue hexagons, mannose.
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Figure 2: Schematic representation of the proposed DIM biosynthesis pathway.
Adapted from (88). The proposed roles of the various FAAL and PKS proteins encoded by the
DIM locus in M. tuberculosis are depicted. R = C2H5 or CH3. KS, ketosynthase; AT,
acyltransferase; DH, dehydratase; ER, enoylreductase; KR, ketoreductase; ACP, acyl carrier
protein.
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Figure 3: Representative structures of mycobacterial PGLs and PDIMs.
Adapted from (1). The carbon-chain variability and glycosyl unit represented are from main
variants found in the opportunistic human pathogen Mycobacterium marinum. m and m’: 16 –
20, n: 16 – 22, p: 14 – 22.
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Figure 4: Conservation of M. marinum and M. tuberculosis chromosomal loci involved in
PGL-PDIM production.
Adapted from (1). The five M. marinum genes targeted for mutational analysis (∆, deletion; ∗,
amino acid substitution) in this study and their respective orthologs in M. tuberculosis are
highlighted with pattern-filled arrows. †, pks15/1 is essential for PGL production. The gene
pks15/1 is disrupted (split into pks1 and pks15) by natural mutations in M. tuberculosis H37Rv
and other Euro-American lineage strains, thus leading to PGL-deficiency (83,109). Additional
genes implicated in PGL and/or PDIM production located downstream fadD29 are not depicted.
Adapted from (1,78).
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Figure 5: Two possible mechanisms for transfer of p-hydroxyphenylalkanoate (PHPA)
intermediates to PpsA in M. marinum.
Adapted from (1). (A) PHPA-AMP ligase-dependent model. The model includes the release of
PHPAs thioesterified to Pks15/1’s ACP domain (A1), activation of free PHPAs by a PHPAAMP ligase (A2), PHPA-AMP ligase-dependent loading of PHPAs onto PpsA’s ACPL domain
(A3), and captured of the ACPL domain-bound PHPAs by PpsA’s KS domain to yield the fully
loaded PpsA (boxed) ready for KS domain-dependent decarboxylation/condensation.
(B) Direct KS domain capture model. In this model, the fully loaded PpsA (boxed) is generated
directly by the capture of Pks15/1-bound PHPAs by PpsA’s KS domain (B1), thus bypassing the
need for steps A1 through A4. Decarboxylation/condensation leads to extension of PHPAs by a
2-carbon unit via the first non-iterative extension cycle in the formation of phenolphthiocerols.
In the scheme, the depicted carbon-chain variability in the PHPA-S-Pks15/1 thioester
intermediate is that expected during synthesis of M. marinum PGLs. Adenylated PHPAs are
shown bound to the PHPA-AMP ligase via noncovalent linkages (by analogy to other acyl
adenylating enzymes). PpsA’s C-terminal ACP domain is shown loaded (AT domaindependent) with the malonyl-CoA-derived extender unit. Thiol groups of the
phosphopantetheinyl group in the ACP domains and the catalytic Cys in the KS domain are
depicted. The hydroxyl group in the extended PHPAs generated from the keto group by action
of the KR domain of PpsA is shown. Sections of the PHPA intermediates are color-coded based
on origin: blue, derived from a p-hydroxybenzoic acid starter unit; red, derived from malonyl
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extender units via iterative extension cycles; black, section derived from a malonyl extender unit
via a non-iterative extension cycle.
Domain abbreviations: A, adenylation; ACP, acyl carrier protein; ACPL, loading acyl carrier
protein; AT, acyltransferase; DH dehydratase; ER, enoylreductase; KR, ketoreductase; KS,
ketosynthase.
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Figure 6: Mutagenesis cassette-delivery suicide vectors used for construction of M.
marinum mutants.
Adapted from (1). The predicted translational products of the gene remnants or the amino acid
substitutions in the mutagenesis cassette-delivery vectors are shown. The deletion/mutation
point is flanked by ca. 1.0 kb of downstream and upstream wild-type sequence for homologous
recombination with the chromosome.
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Figure 7: Mutant verification analysis.
Adapted from (1). Each chromosomal deletion was confirmed by PCR using two independent
primer pairs. One primer pair was used to verify the expected ~2-kb deletion at the deletion site
(A). A second primer pair was used to confirm the elimination of the target gene from the
chromosome (B). The nucleotide substitutions in Mm ppsAS-A introducing Ser-to-Ala
substitutions and a BssHII restriction site were confirmed by sequence analysis (C).
Amplicon information for the agarose gel electrophoresis image shown in panel A: lane 2, Mm
WT (4,110-bp amplicon expected with primers SalIFadD22OF and NotIFadD22OR); lane 3, Mm
ΔfadD22 (2,016-bp amplicon expected with SalIFadD22OF and NotIFadD22OR); lane 4, Mm
WT
(3,658-bp
amplicon
expected
with
primers
HindIIIMarFadD26OF
and
KpnIMarFadD26OR); lane 5, Mm ΔfadD26 (1,930-bp amplicon expected with
HindIIIMarFadD26OF and KpnIMarFadD26OR); lane 6, Mm WT (3,639-bp amplicon expected
with primers BamHIMarFadD28OF and NotIMarFadD28OR); lane 7, Mm ΔfadD28 (1,928-bp
amplicon expected with BamHIMarFadD28OF and NotIMarFadD28OR); lane 8, Mm WT
(3,804-bp amplicon expected with primers BamHIMarFadD28OF and NotIMarFadD28OR); lane
9, Mm ΔfadD29 (1,966-bp amplicon expected with HindIIIMarFadD29OF and
PmlIMarFadD29OR).
Amplicon information for the agarose gel electrophoresis image shown in panel B: lane 11, Mm
WT, 2,156-bp amplicon expected with primers HindIIIFadD22For and HpaIFadD22Rev; lane
12, Mm ΔfadD22, no amplicon expected with HindIIIFadD22For and HpaIFadD22Rev; lane 13,
Mm WT, 1,794-bp amplicon expected with primers pCP0ForMarFadD26 and
pCP0RevMarFadD26; lane 14, Mm ΔfadD26, no amplicon expected with pCP0ForMarFadD26
and pCP0RevMarFadD26; lane 15, Mm WT, 1,919-bp amplicon expected with primers
pCP0ForMarFadD29 and pCP0RevMarFadD29; lane 16, Mm ΔfadD29, no amplicon expected
with pCP0ForMarFadD29 and pCP0RevMarFadD29; lane 18, Mm WT, 1,779-bp amplicon
expected with primers pCP0ForMarFadD28 and pCP0RevMarFadD28; lane 19, Mm ΔfadD28,
no amplicon expected with pCP0ForMarFadD28 and pCP0RevMarFadD28. DNA ladder
marker: lanes 1, 10, and 17. The sizes of relevant DNA makers flanking the PCR product of of
interests are indicated. WT, wild-type. Mm, M. marinum. See Table 3. PCR primer pairs and
amplicon information used in mutant screening and verification.
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Figure 8: Inactivation of PpsA’s ACPL domain leads to a PGLˉ PDIMˉ phenotype in M.
marinum.
Adapted from (1). Radio-TLC analysis of [14C]-labeled PGLs (A) and [14C]-PDIMs (B) from
Mm wt + pCP0 (WT), Mm ppsAS-A + pCP0 (ppsAS-A), and Mm ppsAS-A + pCP0-ppsA (ppsAS-A c). The wild-type (WT) and mutant M. marinum (Mm) strains carried the vector pCP0 so they
could be cultured in the same kanamycin-containing medium used for the complemented Mm
ppsAS-A + pCP0-ppsA strain. TLC solvent systems used are indicated. CHCl3, chloroform;
MeOH, methanol; PE, petroleum ether; Et2O, diethyl ether.
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Figure 9: Mutational analysis points at M. marinum FadD29 as a PHPA-AMP ligase
candidate.
Adapted from (1). Radio-TLC analysis of [14C]-labeled PGLs (A) and [14C]-PDIMs (B) from
Mm wt + pCP0 (WT), Mm ∆fadD22 + pCP0 (22m), Mm ∆fadD22 + pCP0-fadD22 (22c), Mm
∆fadD26 + pCP0 (26m), Mm ∆fadD26 + pCP0-fadD26 (26c), Mm ∆fadD28 + pCP0 (28m), Mm
∆fadD28 + pCP0-fadD28 (28c), Mm ∆fadD29 + pCP0 (28m), and Mm ∆fadD29 + pCP0-fadD29
(29c). The wild-type (WT) and mutant M. marinum (Mm) strains carried the vector pCP0 so
they could be cultured in the same kanamycin-containing medium used for the complemented
strains. TLC solvent systems used are as depicted in Figure 8.
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Figure 10: Congo red binding properties of M. marinum strains.
Adapted from (2). Plates of supplemented or nonsupplemented 7H11 medium without or with
Congo red (CR) were spot-inoculated with M. marinum cultures, incubated for growth, and
imaged. The results with the ∆tesA and ∆fadD22 mutants are equivalent to those seen with the
rest of the mutants, except by the complementation differences noted in the text. The data is
representative of three experiments. WT, M. marinum wild-type.
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Figure 11: Ethidium bromide accumulation rate of M. marinum strains.
Adapted from (2). Rates of ethidium bromide (EtBr) accumulation were determined as the slopes
of linear regression lines fitted to fluorescence-time datasets generated using a multiwell platebased assay. The results correspond to means and SEM of five experiments. Student’s t-test p
values versus wild-type (WT): *, < 0.05; **, < 0.01.
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Figure 12: Antibiotic susceptibility of M. marinum strains.
Adapted from (2). Fold-change in MIC values between the wild-type (WT) strain and the
mutants (A) or the mutants constitutively expressing an episomal WT copy of the deleted gene
(B) are shown. Dose-response studies were conducted using a standard microdilution method.
MIC values for fold-change determinations were derived from sigmoidal curves fitted to doseresponse datasets. A strain was defined as having an altered antibiotic susceptibility when it
displayed >2-fold change (dotted line) relative to WT. The results represent means and SEM of
three experiments.
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Figure 13: Biofilm formation by M. marinum strains.
Adapted from (2). Biofilm formation on a solid surface was investigated using the MBEC
device, which consists of a standard 96-well plate with a 96-well plate lid containing 96
polystyrene pegs that fit into the wells and onto which wild-type (WT) M. marinum forms
biofilms. Representative peg (A) and biofilm microcolony (B) images from M. marinum WT
and from two mutants and their corresponding complemented strains are shown. The results
with these mutants are equivalent of those seen with the rest of the mutants. Biofilm formation
on the pegs was quantified using a standard colorimetric method (C). The results represent
means and SEM of a minimum of six experiments. Student’s t-test p values versus WT: *, <
0.05; **, < 0.01. All M. marinum strains formed comparable pellicles on the surface of the
liquid growth medium. The representative pellicle shown is for the WT strain (D).
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Figure 14: Inhibition of D. discoideum by M. marinum strains.
Adapted from (2). The virulence of the M. marinum strains was assessed using a D. discoideum
inhibition assay. The highest amoeba inoculum inhibited by each strain was considered a
measure of its amoeba inhibition capacity. The fold reduction in virulence of each strain relative
to M. marinum wild-type (WT) is shown at the base of each bar for the mutants and above the
bar for M. smegmatis (Msm). The results correspond to means and SEM of three experiments.
**, Student’s t-test p < 0.01 (versus WT).
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TABLES
Table 1: Bacterial strains
Adapted from (1).

Strain

Characteristics

E.coli DH5α

Cloning host

Source/
Reference
Invitrogen
American

M.marinum strain M

Wild-type

Culture
Collection

M.marinum ΔfadD22

Carries an in-frame, unmarked fadD22 deletion

(1)

M.marinum ΔfadD26

Carries an in-frame, unmarked fadD26 deletion

(1)

M.marinum ΔfadD28

Carries an in-frame, unmarked fadD28 deletion

(1)

M.marinum ΔfadD29

Carries an in-frame, unmarked fadD29 deletion

(1)

Carries a ppsA mutated allele with a Ser-to-Ala substitution
M.marinum ppsAS-A

disrupting the phosphopantetheine attachment site of the (1)
ACPL domain
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Type

Table 2: Plasmids
Adapted from (1)
Source

Plasmid

Characteristics

pCR2.1-TOPO

Cloning vector, kanamycin and ampicillin resistance

Invitrogen

p2NIL

Vector with kanamycin resistance gene and OriE

(125)

pGOAL19

Vector with sacB-lacZ PacI cassette, hygromycin (125)
resistance, OriE

p2NILGOALc-ΔfadD22c

fadD22 deletion cassette delivery vector

(1)

p2NILGOALc-ΔfadD26c

fadD26 deletion cassette delivery vector

(1)

p2NILGOALc-ΔfadD28c

fadD28 deletion cassette delivery vector

(1)

p2NILGOALc-ΔfadD29c

fadD29 deletion cassette delivery vector

(1)

p2NILGOALc-ppsAc

ppsA mutagenesis cassette delivery vector

(1)

pCP0

Mycobacterial expression vector, kanamycin resistance

(89)

pCP0-FadD22

pCP0 derivative expressing FadD22

(1)

pCP0-FadD26

pCP0 derivative expressing FadD26

(1)

pCP0-FadD28

pCP0 derivative expressing FadD28

(1)

pCP0-FadD29

pCP0 derivative expressing FadD29

(1)

pCP0-PpsA

pCP0 derivative expressing PpsA

(1)

Reference
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or

Table 3. PCR primer pairs and amplicon information used in mutant screening and
verification.
Adapted from (1)
Amplicon (bp)
Mutant
probed

Primer
name

Primer sequence
(5’-3’)

SalIFadD22OF

GTCGACTCACCATCGTGGAGTTCGCCAGCTGG

NotIFadD22OR

GCGGCCGCACGCGCTGGGCGAGCCCATT

HindIIIFadD22For

AAGCTTGCTAGGGCGGTCATCCAATAATGC

HpaIFadD22Rev

GTTAACCTCAGTTGCTCCTGTTCATGATTC

Mutant
strain

Wild-type
strain

2,016

4,110

0

2,156

1,930

3,658

0

1,794

1,928

3,639

0

1,779

1,966

3,804

0

1,919

ΔfadD22

HindIIIMarFadD26OF AAGCTTATGAAGAATTTCGAGTGGGAGTCCTGCCGACATT
KpnIMarFadD26OR

GGTACCTCCGCGAAACACCGCCGGAGACAACAGCAAATT

ΔfadD26
pCP0ForMarFadD26 GAATTCAATGGGAGTGTAGTGCGATGCCGG
pCP0RevMarFadD26 AAGCTTATGCTCGGTGTCATACCGTCACGT
BamHIMarFadD28OF GGATCCACCCGCTTCACCTCTTCGAGGAAAACTGGAAA
NotIMarFadD28OR

GCGGCCGCTTCGGGCCAGCAGTAGCGGGGCGGTGAGTAT

ΔfadD28
pCP0ForMarFadD28 AAGCTTCGGTAACGTGATGCCCATGAGTGT
pCP0RevMarFadD28 GCTAGCTTGACACGCTAGACGTCCAGGCGG
HindIIIMarFadD29OF AAGCTTACCACGGTCTGAGGTATCTGCTGGTGATCAAT
PmlIMarFadD29OR

CACGTGAAAACCTGCACCAGCTCCGGCGAATCCGGCATA

ΔfadD29
pCP0ForMarFadD29 GAATTCTCTTCCGTCGAGAGCAAGGATGAT
pCP0RevMarFadD29 AAGCTTTAAAGCCGCCAACATGCCGTCATG
ppsAACPMutOF

AAGCTTCGCTCCCTTCAACCTCAGCCCCGCTGCG

ppsAACPMutOR

CCGGCACCTTCACCACGGACGAAACCGTCG

pm7

CGATCGAGGACTTGCGGTCACAG

pm8

GGTGGCCGACGTCGTGCTGGTAC

1,832
(split by
BssHII)

1,832
(no split by
BssHII)

ΔppsAS-A
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526
(Ser-to-Ala
mutations)

526
(wild-type
sequence)

Table 4. PCR primer pairs and amplicons pertaining to construction of mutagenesis cassettes & expression plasmids
Adapted from (1)

Amplicon (bp)
ΔfadD22c 5’ arm (1,025)

ΔfadD22c 3’ arm (1,018)

ΔfadD22c full-length (2,016)
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ΔfadD26c 5’ arm (1029)

ΔfadD26c 3’ arm (958)

ΔfadD26c full-length (1952)

ΔfadD28c 5’ arm (983)

ΔfadD28c 3’ arm (972)

ΔfadD28c full-length (1922)

Primer name

Primer sequence (5’-3’)

SalI FadD22 OF

GTCGACTCACCATCGTGGAGTTCGCCAGCTGG

FadD22 IR

TCCTGTTCATGATTCCCGCATTATTGGATGACCGCCCTA

FadD22 IF

ATCCAATAATGCGGGAATCATGAACAGGAGCAACTGAG

NotI FadD22 OR

GCGGCCGCACGCGCTGGGCGAGCCCATT

SalI FadD22 OF

GTCGACTCACCATCGTGGAGTTCGCCAGCTGG

NotI FadD22 OR

GCGGCCGCACGCGCTGGGCGAGCCCATT

HindIIIMarFadD26OF

AAGCTTATGAAGAATTTCGAGTGGGAGTCCTGCCGACATT

FadD26IR

TCATACCGTCACGTCGGTCACCGGCATCGCACTACACTCCCATTC

FadD26IF

ATGCCGGTGACCGACGTGACGGTATGACACCGAGCATCGGTG

KpnIMarFadD26OR

GGTACCTCCGCGAAACACCGCCGGAGACAACAGCAAATT

HindIIIMarFadD26OF

AAGCTTATGAAGAATTTCGAGTGGGAGTCCTGCCGACATT

KpnIMarFadD26OR

GGTACCTCCGCGAAACACCGCCGGAGACAACAGCAAATT

BamHIMarFadD28OF

GGATCCACCCGCTTCACCTCTTCGAGGAAAACTGGAAA

FadD28IR

CTAGACGTCCAGGCGGGGGAACGCACACTCATGGGCATCACGTTA

FadD28IF

ATGAGTGTGCGTTCCCCCGCCTGGACGTCTAGCGTGTCAACCGAC

NotIMarFadD28OR

GCGGCCGCTTCGGGCCAGCAGTAGCGGGGCGGTGAGTAT

BamHIMarFadD28OF

GGATCCACCCGCTTCACCTCTTCGAGGAAAACTGGAAA

NotIMarFadD28OR

GCGGCCGCTTCGGGCCAGCAGTAGCGGGGCGGTGAGTAT

Comments

Full-length cloned into
p2NIL as a SalI-NotI
fragment.

Full-length cloned into
p2NIL as a HindIII-KpnI
fragment.

Full-length cloned into
p2NIL as a BamHI-NotI
fragment.

Amplicon (bp)

Primer name

Primer sequence (5’-3’)

Comments

HindIII Mar FadD29 OF AAGCTTACCACGGTCTGAGGTATCTGCTGGTGATCAAT
ΔfadD29c 5’ arm (982)
Mar FadD29 IR

ATGCGGACCGGTCCAAAGTCCATGATCATCCTTGCTCTCGACGGAA

Mar FadD29 IF

AGGATGATCATGGACATTTGGACCGGTCCGCATGACGGCATGTT

PmlI Mar FadD29 OR

CACGTGAAAACCTGCACCAGCTCCGGCGAATCCGGCATA

ΔfadD29c 3’ arm (1,015)

Full-length cloned into
p2NIL as a HindIII-PmlI
fragment.

HindIII Mar FadD29 OF AAGCTTACCACGGTCTGAGGTATCTGCTGGTGATCAAT
ΔfadD29c full-length (1,966)
PmlI Mar FadD29 OR

CACGTGAAAACCTGCACCAGCTCCGGCGAATCCGGCATA

ppsA ACP Mut OF

AAGCTTCGCTCCCTTCAACCTCAGCCCCGCTGCG

ppsA ACP Mut IR

AGCACAACGGCGTCGCGCGCGGCCACGCCGAGGTCA

ppsA ACP Mut IF

TGACCTCGGCGTGGCCGCGCGCGACGCCGTTGTGCT

ppsA ACP Mut OR

CCGGCACCTTCACCACGGACGAAACCGTCG

ppsA ACP Mut OF

AAGCTTCGCTCCCTTCAACCTCAGCCCCGCTGCG

ppsA ACP Mut OR

CCGGCACCTTCACCACGGACGAAACCGTCG

ΔppsAc 5’ arm (950)
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ΔppsAc 3’ arm (912)

Full-length cloned into
p2NIL as a as HindIII-

ΔppsAc full-length (1,832)

HpaII insert.

Table 5: Mycobacterial strains
Strain

Characteristics

Reference

M.
marinum
M
(ATCC BAA-535)

human clinical isolate, wild-type, PDIM+ PGL+

(166)

M. marinum ΔfadD22

fadD22 (MMAR_1761 / MMAR_RS08725)* deletion,
PDIM+ PGLˉ

(1)

M. marinum ΔfadD22-c

fadD22 deletion, carries a pCP0 vector derivative expressing
fadD22, PDIM+ PGL+ (complemented strain)

(1)

M. marinum ΔfadD26

fadD26 (MMAR_1777 / MMAR_RS08805) deletion, PDIMˉ
PGL+

(1)

M. marinum ΔfadD26-c

fadD26 deletion, carries a pCP0 derivative expressing
fadD26, PDIM+ PGL+ (complemented strain)

(1)

M. marinum ΔfadD28

fadD28 (MMAR_1765 / MMAR_RS08745) deletion, PDIMˉ
PGLˉ

(1)

M. marinum ΔfadD28-c

fadD28 deletion, carries a pCP0 derivative expressing
fadD28, PDIM+ PGL+ (complemented strain)

(1)

M. marinum ΔfadD29

fadD29 (MMAR_1759 / MMAR_RS08715) deletion, PDIM+
PGLˉ

(1)

M. marinum ΔfadD29-c

fadD29 deletion, carries a pCP0 derivative expressing
fadD29, PDIM+ PGL+ (complemented strain)

(1)

M. marinum ΔtesA

tesA (MMAR_1778 / MMAR_RS08810) deletion, PDIMˉ
PGLˉ

(89)

M. marinum ΔtesA-c

tesA deletion, carries a pCP0 derivative expressing tesA,
PDIM+ PGL+ (complemented strain)

(89)

M. marinum ΔpapA5

papA5 (MMAR_1768 / MMAR_RS08760) deletion, PDIMˉ
PGLˉ

(92)

M. marinum ΔpapA5-c

papA5 deletion, carries a pCP0 derivative expressing papA5,
PDIM+ PGL+ (complemented strain)

(92)

nonpathogenic species, lacks the PDIM/PGL biosynthetic
pathway

(166)

M. smegmatis
(ATCC 700084)

MC2155

Adapted from (2).* Original and re-annotated locus tag designations as per National Center for
Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/) are provided for each gene.
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Table 6: Roles of the gene products and the previously determined phenotypes of each deletion mutant and corresponding
complemented strain.
Adapted from (2).
M. marinum deletion
mutant
PDIM
PGL
Production
Production
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Complementation
(Lipid
Production)

Reference

no

yes

(89)

no

no

yes

(92)

no

no

yes

(1)

yes

no

yes

(1)

yes

no

yes

(1)

no

yes

yes

(1)

Enzyme

Function

TesA

Thioesterase required for release of polyketide
synthase bound products and/or acyl
intermediates

no

PapA5

Acyltransferase required for esterification of
phthiocerols and phenolphthiocerols with
mycocerosic acids

FadD28

Activation and loading of fatty acids required for
mycocerosic acid synthesis

FadD22

FadD29

FadD26

Activation and loading of p-hydroxybenzoic acid
precursor required for phenolphthiocerols
synthesis
Activation and loading of phydroxyphenylalkanoates intermediates
precursors required for phenolphthiocerol
synthesis
Activation and loading of fatty acids required for
phthiocerol synthesis
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